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Preface	
 
The	following	dissertation	was	written	by	the	author.	The	‘Results’	part	consists	of	two	
published	manuscripts,	a	manuscript	in	preparation	and	additional	preliminary	data.	In	
(Skachokova	et	al.	2015)	the	author	executed	the	experiments,	analysis	and	writing	of	the	
manuscript.	In	(Ozcelik,	Sprenger,	Skachokova	et	al.	2016)	the	author	contributed	with	some	
of	the	experiments,	analysis	and	final	writing,	as	additionally	stated	(see	‘Results’	part).	The	
additional	data	is	a	result	of	own	work.	
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Summary 
	
Alzheimer’s	disease	(AD)	is	the	most	common	neurodegenerative	disorder,	and	its	
prevalence	is	still	increasing.	However,	currently	there	are	no	treatment	options	available,	
nor	reliable	presymptomatic	biomarkers	for	its	diagnosis.	Neuropathologically,	AD	is	
characterized	by	aggregates	(plaques	and	cerebrovascuar	deposits;	and	tangles)	composed	
of	two	different	proteins:	amyloid-β	(Aβ)	and	tau,	respectively.	Brain	derived	Aβ	and	tau	
exhibit	prion-like	properties,	as	based	on	recent	studies.	
Small	and	soluble	Aβ	species	have	been	identified	as	the	most	potent	Aβ	seeds,	and	they	
may	be	present	in	the	CSF	which	could	be	of	a	diagnostic	value.	Injection	of	CSF	obtained	
from	AD	patients	into	APP23	transgenic	mice	however	did	not	result	into	induction	or	
acceleration	of	amyloidosis,	indicating	that	human	CSF	Aβ	is	not	seed	competent,	in	
contrast	to	brain	Aβ	(Fritschi	et	al.	2014).	In	order	to	test	this	hypothesis	further,	we	
injected	susceptible	mice	with	APP23	mice’	CSF,	containing	Aβ	at	higher	amounts	than	the	
human	CSF,	and	sacrificed	the	mice	after	longer	seeding	time.	As	a	result,	we	did	not	see	a	
significant	seeding	effect,	confirming	that	CSF	Aβ	does	not	show	relevant	prion-like	
properties	in	vivo.		
Next,	we	looked	at	the	prion-like	properties	of	tau	in	the	CSF.	Since	tau	concentration	in	the	
CSF	increases	with	progression	of	AD,	unlike	Aβ	levels,	it	is	possible	that	seeding	competent	
tau	species	might	reach	the	CSF	compartment.	For	this	purpose,	we	collected	CSF	from	
aged,	tangle-bearing	P301S	mice	and	injected	it	into	young,	pretangle	stage	P301S	mice.	As	
a	result,	we	observed	significantly	higher	number	of	hyperphosphorylated	tau	inclusions	in	
the	injected	hippocampus,	indicating	that	CSF	tau	can	induce	tau	hyperphosphorylation	in	
the	host	mice.	This	could	be	indicative	of	an	early	prion-like	seeding	response.	We	then	
investigated	whether	CSF	obtained	from	human	tauopathy	patients	could	induce	tau	
aggregation	using	the	same	methodology.		The	collection	of	human	CSF	samples	as	well	as	
the	analysis	of	human	CSF	seeded	mice	is	still	ongoing.		
 
Tau	protein	fragments	have	been	identified	in	both	the	CSF	and	the	brain	of	AD	patients,	
however	it	is	not	clear	what	is	their	role	in	the	progression	of	the	disease.	Recent	studies	
suggest	that	tau	fragmentation,	rather	than	aggregation	per	se,	may	play	an	important	role	
in	neurodegeneration.	To	study	the	relation	between	truncated	and	full-length	tau	in	vivo	
and	shed	more	light	on	this	question,	we	used	an	inducible	mouse	line	expressing	truncated	
3R	tau,	and	crossed	it	with	full-length	tau-expressing	mice	(3R,	or	4R	with	and	without	a	
mutation).	As	a	result,	mice	exhibited	severe	neuronal	loss	and	motor	palsy	in	the	absence	
of	tau	aggregation.	However,	they	recovered	once	the	expression	of	fragmented	tau	was	
ceased,	except	for	the	3R-expressing	mice.	This	shows	the	importance	of	fragmented	tau	for	
toxicity	and	points	at	new	therapeutic	targets	in	the	treatment	of	tauopathies.		
	
Taken	together,	the	results	presented	here	point	at	the	possible	use	of	CSF	tau	in	the	
development	of	future	AD	diagnostic	essays,	and	implicate	tau	truncation	as	a	potential	
pharmacological	target	in	tauopathies.		
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Introduction 
 
Alzheimer’s	disease	is	a	progressive	neurodegenerative	disorder	with	an	increasing	
prevalence	and	deleterious	life	consequences.	It	was	first	described	by	Alois	Alzheimer	more	
than	a	century	ago,	and	even	though	our	understanding	of	the	disease	has	grown	
substantially	since	then,	current	treatment	option	is	still	lacking	(Fig.	1).	This,	together	with	
AD’s	better	mechanistic	understanding,	presymptomatic	diagnosis	and	finally	prevention,	is	
one	of	the	challenges	facing	contemporary	biomedical	research	and	our	society,	as	a	whole.	
	
	
Alzheimer’s disease 
	
Epidemiology and risk factors 
	
There	are	currently	40	million	people	living	with	dementia	worldwide,	and	this	number	is	
expected	to	double	every	20	years,	as	developing	countries	are	at	increasing	risk	with	their	
younger	populations	(Prince	et	al.	2013).	Alzheimer’s	disease	(AD)	is	the	most	common	type	
of	dementia,	with	roughly	30%	of	early	onset	dementia	cases	(before	65	years	of	age)	being	
attributed	to	AD	(Lambert	et	al.	2014).	In	Switzerland	alone,	there	are	more	than	100	000	
AD	patients	at	present,	and	3	times	more	are	expected	by	2050	(Blankman	et	al.	2012).	Also,	
there	is	a	trend	for	decreasing	age-specific	incidence	of	dementia	during	the	last	years,	
probably	explained	by	lowering	vascular	risk	factors	among	others,	indicating	the	complexity	
of	the	disease.	There	are	few	known	genes	implicated	in	a	small	subpopulation	of	cases,	
however	the	majority	of	AD	cases	are	sporadic,	due	to	yet	unknown	cause(s).	
Age	is	the	main	risk	factor	for	dementia	and	AD,	however,	a	variety	of	lifestyle	factors	have	
been	implicated	in	the	disease	pathogenesis	as	well.	Those	include	cardiovascular	health,	
diabetes,	obesity,	physical	and	mental	activity,	depression,	smoking	and	level	of	education.		
However,	their	exact	roles	in	the	disease	are	yet	to	be	elucidated	as	AD	develops	over	a	long	
preclinical	period	of	several	decades	and	those	may	be	rather	causalities	(Scheltens	et	al.	
2016).	
	
	
	
Figure	1.	Original	drawing	by	Alois	Alzheimer	(left)	from	1907	showing	the	neurofibrillary	lesions	present	in	the	
brain	of	his	patient,	and	a	schematic	drawing	illustrating	most	molecules	and	cellular	processes	involved	in	AD	
known	today	(right;	adapted	from	(Holtzman	et	al.	2011)).	Despite	increased	understating	of	the	mechanisms	
and	risk	factors	involved,	the	exact	cause	leading	to	AD	is	still	unknown.	
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Symptoms 
	
The	first	ever	described	AD	patient,	Auguste	Deter,	died	in	the	year	1907	while	exhibiting	no	
sense	of	time	and	place,	impaired	episodic	memory,	delusions,	disrupted	sleep	and	
temporary	vegetative	states,	and	became	ultimately	completely	dependent	on	others	
(Alzheimer	et	al.	1907).	A	century	later	she	was	diagnosed	as	a	carrier	of	presenilin	1	
(PSEN1)	mutation	and	so	exhibited	a	rare	form	of	an	early,	genetic	AD	(Muller	et	al.	2013).	
In	current	clinical	practice	aged	individuals	with	(sporadic)	AD	can	have	similar	complaints,	
mainly	memory	disturbances	and	executive	dysfunction,	but	also	in	some	atypical	cases	
language	and	visual	problems	which	may	precede	memory	impairment.	Current	clinical	
diagnosis	depends	not	only	on	neuropsychological	testing,	but	also	on	a	set	of	criteria	
including	brain	imaging	(MRI,	PET)	and	CSF	biomarkers	(McKhann	et	al.	2011). 	
Genetic risk factors 
	
A	few	mutations	have	been	linked	to	the	rare	familial	forms	of	AD,	implicating	amyloid	beta	
and	tau	as	the	main	mediators	in	the	disease	(Fig.	2).	Amyloid	precursor	protein	(APP)	is	the	
precursor	of	Aβ,	and	different	mutations	in	the	gene	affect	Aβ	production	and	aggregation	
(Scheltens	et	al.	2016).	PSEN1	and	PSEN2	regulate	gamma-secretase,	which	cleaves	APP.		
Mutations	in	PSEN	lead	to	the	generation	of	longer	Aβ	peptides,	and	have	been	associated	
with	early	disease	onset	and	more	rapid	progression	(Scheuner	et	al.	1996).	Mutations	in	
Tau	gene	cause	neurodegeneration	without	the	formation	of	amyloid	plaques,	as	seen	in	
patients	with	Frontotemporal	dementia.	The	interplay	of	Aβ	and	tau	is	still	a	matter	of	
debate,	most	likely	they	both	act	in	parallel	causing	AD	(Small	&	Duff	2008).		
In	the	sporadic	AD,	the	major	genetic	risk	factors	known	so	far	is	the	APOE4	allele,	as	in	
homozygous	individuals	it	increases	the	risk	of	AD	by	50%	(Genin	et	al.	2011).	APOE	has	
been	implicated	in	Aβ	clearance	(Castellano	et	al.	2011).	In	addition,	genes	involved	in	
immune	system	and	inflammation,	together	with	lipid	metabolism	have	been	identified	as	
linked	to	AD	(Guerreiro	&	Hardy	2014).		
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Figure	2.	APP	misprocessing	together	with	tau	hyperphosphorylation	and	other	post	translational	
modifications	have	been	implicated	in	their	aggregation	and	subsequent	cell	death,	as	seen	in	AD.	Adapted	
from	(Kang	et	al.	2013).	
	
Diagnosis 
	
At	present,	diagnosis	of	dementia	is	based	on	neuropsychological	testing,	brain	imaging	and	
the	use	of	CSF	biomarkers		(Cummings	et	al.	2004).	Currently	AD	diagnostic	use	MRI	to	
assess	changes	in	cortical	thickness,	hippocampal	volume	and	vascular	brain	changes	
(Frisoni	et	al.	2010).	In	addition,	PET	scan	which	measures	glucose	uptake	by	neurons	and	
indicates	early	synaptic	changes	is	a	valuable	diagnostic	tool	for	dementia	(Perani	et	al.	
2014).	PET	with	Aβ	ligands	is	relatively	novel	and	with	high	accuracy,	however	it	has	mostly	
exclusionary	value,	as	brain	amyloidosis	also	occurs	in	healthy	aged	people	(Marchant	et	al.	
2012).	As	a	result,	Aβ	imaging	is	costly	and	cannot	alone	provide	a	definite	diagnosis.	
CSF	is	in	a	constant	exchange	with	the	brain	interstitial	fluid,	which	is	in	a	direct	contact	with	
the	neurons.	In	this	sense,	characterization	of	CSF	proteins	may	describe	molecular	events	
occurring	in	the	live	neurons,	and	could	help	our	understanding	of	neurodegenerative	
diseases	(Fig.	3).	CSF	biomarkers	routinely	used	in	AD	diagnosis	are	amyloid-β	(showing	
cortical	amyloid	deposition),	total	tau	(intensity	of	neurodegeneration),	and	phosphorylated	
tau	(correlated	with	neurofibrillary	pathology)	(Blennow	et	al.	2010a).	They	have	high	
sensitivity	and	specificity	(85-90%),	and	allow	to	differentiate	AD	from	mild	cognitive	
impairment	stage	in	patients	(Shaw	et	al.	2009).	However,	standardization	of	CSF	analysis	
for	routine	laboratory	use	is	still	ongoing	and	there	is	significant	measurements	variability	at	
present	(Scheltens	et	al.	2016).	
Finally,	the	combination	of	imaging	and	CSF	markers	has	a	good	positive	and	good	negative	
predictive	value	to	differentiate	AD	from	normal	aging	in	patients	with	mild	cognitive	
impairment.	
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Figure	3.	Present	CSF	biomarkers	for	dementias.	Adapted	from	(Wang	et	al.	2012).	
 
Pathology 
	
Alois	Alzheimer	first	described	the	senile	plaques	and	neurofibrillary	tangles	(NFTs)	typical	
of	the	disease	(Fig.	4)	(Alzheimer	et	al.	1906).	Today	we	know	that	the	cerebral	plaques	
consist	of	Aβ	peptide,	and	neurofibrillary	tangles	are	composed	of	tau	protein	(Hardy	&	
Selkoe	2002).	The	pathology	precedes	and	may	parallel	the	observed	neurodegeneration	
(i.e.	neuronal	cell	loss	and	atrophy).	However,	the	exact	link	between	protein	aggregation	
and	toxicity	is	still	unclear.	Neuronal	lesions	primarily	in	the	perirhinal	and	entorhinal	cortex,	
the	hippocampus	and	the	cerebral	cortex	(Mouton	et	al.	1998),	as	well	as	synaptic	and	
dendritic	loss	parallel	the	disease	development	(Terry	et	al.	1991).	While	the	pathological	
lesions	were	considered	main	players	in	AD	pathogenesis	before,	more	and	more	evidences	
suggest	the	importance	of	pre-aggregation	factors	in	Aβ	and	tau	toxicity.	
	
	
Figure	4.	AD	pathological	hallmarks	are	senile	plaques	in	the	brain	made	out	of	Aβ	protein	(left	image),	Aβ	
deposition	in	the	blood	vessel	walls	(middle),	and	NFTs	made	of	aggregated	tau	protein	(right).	Images	
adapted	from	Basler	Neuropathology	and	(Castellani	et	al.	2004).		
 
	
Amyloid-β 
	
Aβ	is	the	main	component	of	senile	plaques,	extracellular	deposits	typical	of	AD	that	are	
surrounded	by	dystrophic	neurites,	activated	microglia	and	reactive	astrocytes	(Masters	et	
al.	1985;	Selkoe	et	al.	1986,	Probst	et	al.	1991).	In	addition	to	brain	parenchyma,	they	may	
be	also	present	in	the	walls	of	blood	vessels	and	periarteriolar	channels,	a	condition	known	
as	cerebral	amyloid	angiopathy	(CAA)	(Tagliavini	et	al.	1988). Aβ	is	a	4	kDa	large	protein	
made	of	39-43	amino	acids,	which	results	from	the	proteolysis	of	the	amyloid	precursor	
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protein	(APP)	(Cappai	&	White	1999)	(Fig.	5).	APP	is	a	transmembrane	glycoprotein,	which	is	
proteolytically	cleaved	by	the	membrane	associated	enzymes	alpha-,	beta-	and	gamma-
secretase.	Cleavage	of	APP	by	beta-secretase	followed	by	gamma-secretase	(via	the	
amyloidogenic	pathway)	results	in	the	generation	of	a	highly	fibrillogenic	Aβ	peptide.	This	
process	requires	the	presence	of	proteins	and	enzymes	such	as	BACE1,	presenilin	complex,	
nicastrin,	and	others.	
 
Figure	5.	Schematic	representation	of	APP	processing	and	Aβ	production.	Adapted	from	(Kahle	&	De	Strooper	
2003).	
	
The	aggregation	of	Aβ	peptide	is	thought	to	be	an	early	event	that	drives	Alzheimer’s	
disease	pathogenesis	and	begins	at	least	a	decade	before	clinical	symptoms	are	detected.	
The	idea	that	the	pathogenesis	of	AD	is	driven	by	the	aggregation	of	Aβ	fibrils,	the	so	called	
“amyloid	cascade”	hypothesis,	has	been	first	suggested	in	1991	(Chartier-Harlin	et	al.	1991).	
According	to	it,	the	progression	of	the	disease,	including	formation	of	neurofibrillary	lesions,	
microglia	activation,	synaptic	dysfunction	and	neuronal	loss,	would	be	an	outcome	of	an	
imbalance	between	Aβ	production	and	clearance.	However,	abundant	cortical	Aβ	deposits	
have	been	found	in	cognitively	healthy	elderly	individuals,	questioning	the	role	of	Aβ	
aggregation	in	memory	loss	and	cell	toxicity	(Dickson	et	al.	1992).	Several	studies	support	a	
modification	of	the	amyloid	cascade	hypothesis	and	suggest	that	Aβ	assembly	into	
neurotoxic	oligomers,	and	not	into	amyloid	plaques,	is	the	major	toxic	effector	in	AD	
pathogenesis	(Klein	et	al.	2001).	Most	probably	fibrillar	amyloid	plaques	serve	as	a	container	
for	the	amyloid	oligomers	or	constitute	a	pool	of	sequestered	soluble	and	precipitated	Aβ.	
They	would,	therefore,	have	a	protective	role	or	simply	constitute	the	end	stage	of	the	Aβ	
cascade	(Masters	et	al.	2006). 
Amyloid-β transgenic mice 
	
To	better	understand	AD	pathophysiology,	different	transgenic	mice	lines	have	been	
created.	Animals	overexpressing	human	APP	are	widely	used	to	model	aspects	of	AD	in	vivo,	
since	they	develop	Aβ	plaques	progressively	with	the	age.	Some	of	the	first	APP	transgenic	
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mice	described	are	the	APP23	line,	carrying	human	APP	gene	with	a	known	London	
mutation,	located	near	the	beta-secretase	cleavage	site	(Sturchler-Pierrat	et	al.	1997).	At	6	
months	of	age,	these	mice	start	developing	plaques,	which	cover	up	to	25%	of	their	
neocortex	and	hippocampus	by	24	months	of	age.	They	also	exhibit	dystrophic	neurites,	
activated	microglia	and	reactive	astrocytes	in	proximity	to	the	plaques.	NFTs	are	lacking,	
however	they	also	develop	CAA	(Winkler	et	al.	2010),	and	show	memory	impairment	at	an	
early	age,	mirroring	some	aspects	of	AD	(Kelly	et	al.	2003).	APP	transgenic	mice	are	a	useful	
model	in	acquiring	basic	understanding	of	Aβ	pathology,	but	also	in	the	development	of	
diagnostic	and	therapeutic	tools.	
 
	
Tau 
	
Another	hallmark	of	AD	pathology	is	the	intracellular	accumulation	of	hyperphosphorylated	
tau	protein	in	NFTs	or	neuropil	threads	(NT).	Tau	is	a	soluble	protein	normally	located	in	the	
axons,	that	promotes	microtubules	stability	in	neuronal	cells.	However,	in	pathological	
conditions,	it	becomes	hyperphosphorylated,	may	localize	in	the	dendrites	and	soma,	where	
it	may	form	intracellular	aggregates.	Tau’s	relationship	with	Aβ	-	whether	parallel	or	
downstream,	is	still	a	matter	of	debate	(Small	&	Duff	2008).	However,	tau	pathology	can	be	
present	independently	of	Aβ	in	a	variety	of	neurodegenerative	disorders	known	as	
tauopathies,	including	progressive	supranuclear	palsy	(PSP),	corticobasal	degeneration	
(CBD),	and	frontotemporal	dementia	(FTD)	(Goedert	et	al.	2010;	Mandelkow	&	Mandelkow	
2011;	Jucker	&	Walker	2013a).	Indeed,	mutation	in	the	tau	gene	was	first	identified	in	cases	
of	frontotemporal	dementia	caused	by	tau	mutation	(FTDP-17,	Goedert	et	al.	2010).	
Tauopathies	may	exhibit	different	morphologies	of	tau	aggregation,	but	they	are	all	
characterized	by	changes	in	personality	and	social	conduct,	and	neuropathologically	by	the	
presence	of	NFTs	and	neuronal	loss	(Fig.	6).		
 
	
	
Figure	6.	Variety	of	aggregated	tau	morphotypes	in	tauopathies.	From	upper	left	corner,	clockwise:	tau	
hyperphosphorylation	as	seen	in	AD;	Gallyas	positive	globose	tangle,	AD;	silver	stained	tufted	actrocyte	in	PSP;	
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hyperphosphorylated	tau	in	Argyrophilic	grain	disease;	hyperphosphorylated	tau	forming	pick	bodies	in	Pick’s	
diseas;	hyperphosphorylated	tau	in	astrocytic	plaques	in	CBD.	Images	adapted	from	(Neumann	et	al.	2009).	
 
 
The	importance	of	tau	for	cellular	functioning	is	reflected	in	its	structural	diversity.	Tau	is	
encoded	by	the	MAPT	gene,	located	on	the	chromosome	17,	and	exists	in	six	different	
isoforms	in	the	adult	human	brain,	products	of	alternative	splicing	of	exons	2,	3	and	10	
(Goedert	et	al.	1989).	The	six	isoforms	differ	by	the	presence	or	absence	of	either	three	(3R	
tau)	or	four	(4R	tau)	microtubule-binding	domains,	and	by	the	number	of	amino	terminal	
(N-	terminal)	inserts.	In	parallel,	the	alternative	splicing	of	exons	2	and	3	results	in	the	
absence	(0N)	or	presence	of	one	(1N)	or	two	(2N)	insert(s)	of	29	amino	acids	in	the	half	N-
terminal	part	of	tau.	Thereby,	alternative	splicing	allows	for	six	different	combinations	
corresponding	to	isoforms	containing	longest	441	aa	tau	(4R2N),	410	aa	(3R2N),	412	aa	
(4R1N),	381	aa	(3R1N),	393	aa	(4R0N)	and	the	shortest,	352	aa	(3R0N)	(Fig.	7).		
 
 
Figure	7.	Schematic	representation	of	the	human	MAPT	(TAU)	gene,	mRNA,	and	all	the	6	tau	protein	isoforms	
as	a	result	of	alternative	splicing.	Adapted	from	(Buée	et	al.	2000). 	
Tau	is	expressed	in	both	central	and	peripheral	nervous	system	and	consists	of	an	N-
terminal	acidic	portion	followed	by	a	proline-rich	region	and	a	C-terminal	tail,	which	is	the	
basic	part	of	the	protein.	Tau	protein	binds	to	the	microtubules	through	the	repeat	regions	
(R1-R4),	and	is	involved	in	tubulin	polymerization	and	microtubules	stabilization	and	
maintenance	of	flexibility	(Fig.	8).	Thereby,	tau	is	important	for	the	maintenance	of	axonal	
transport	and	cell	trafficking,	and	its	function	is	regulated	by	different	kinases	and	
phosphatases	(Weingarten	et	al.	1975;	Bohm	et	al.	1990).	
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Figure	8.	Model	of	microtubule	profilament	with	attached	Tau	and	kinesin.	Tau	is	flexibly	bound	to	tubulin,	
providing	microtubules	dynamic	stability,	while	kinesin	is	involved	in	transport	along	the	microtubules.	
Adapted	from	(Stamer	et	al.	2002).	
 
Tau	is	subjected	to	diverse	post-translational	modifications	such	as	phosphorylation,	
glycosylation,	ubiquitination	or	truncation.	Their	role	in	tau	aggregation	is	still	to	be	
clarified.		
Tau phosphorylation 
	
Phosphorylation	of	tau	is	controlled	by	an	equilibrium	of	a	set	of	protein	kinases	and	
phosphatases.	Dysfunction	of	this	balance	leads	to	the	abnormal	tau	phosphorylation	seen	
in	AD.	Two	main	domains	have	been	distinguished,	depending	on	whether	the	Ser/Thr	
phosphorylation	site	targeting	by	the	kinase	is	followed	by	a	proline	residue	or	not.	Proline-
directed	kinases	include	the	tau	protein	kinase	I	(also	called	glycogen	synthase	kinase	3,	
GSK3),	tau	protein	kinase	II	(cdk5),	kinases	of	the	MAPK	(p38)	or	JNK	families,	as	well	as	
other	stress	kinases,	such	as	cdc2.	In	parallel,	the	protein	kinase	A	(PKA),	protein	kinase	C	
(PKC),	calmodulin	(CaM)	kinase	II,	microtubule-affinity	regulating	kinase	(MARK)	and	casein	
kinase	II	(CKII),	which	modifies	residues	close	to	acidic	residues	mainly	in	protein	region	
corresponding	to	exons	2	and	3,	define	the	non-proline-directed	kinases	(Correas	et	al.	
1992).	It	is	thought	that	changes	in	the	phosphorylation	of	tau	play	an	important	role	in	the	
regulation	of	tau	function	by	modifying	its	affinity	to	microtubules,	and	tau	
hyperphosphorylation	has	been	linked	to	pathogenesis	(Götz	et	al.	1995).		
Tau fragmentation  
	
The	relation	between	tau	aggregation	and	toxicity	is	still	unclear.	Tau	truncation	may	be	
associated	with	tau	aggregation	as	truncated	forms	of	tau	have	been	detected	in	paired	
helical	filaments	(PHFs)	in	AD	brains	(Mena	et	al.	1996).	Truncated	tau	has	also	been	
implicated	in	cognitive	decline	in	patients	(Rohn	et	al.	2002;	Fasulo	et	al.	2000).	It	has	been	
suggested	that	hyperphosphorylation	of	tau	appears	before	its	cleavage	and	that	
fragmentation	occurs	before	NFT	formation	(Mondragón-Rodríguez	et	al.	2008).	In	vitro	
experiments	have	revealed	that	tau	truncated	at	its	C-terminal	domain	was	more	toxic	than	
the	full-length	form	of	tau,	most	probably	due	to	its	faster	and	greater	aggregation	
propensity	(Abraha	et	al.	2000).	Furthermore,	truncation	of	tau	in	the	N-terminal	region	has	
been	previously	reported	and	this	truncation	may	promote	tau	aggregation,	although	its	
pathological	significance	remains	to	be	proven (Horowitz	et	al.	2004).	The	progression	of	
AD	correlates	with	the	extent	of	tau	fragmentation	and	precedes	NFT	formation	(García-
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Sierra	et	al.	2012).	Together,	these	data	put	emphasis	on	the	pathophysiological	importance	
of	truncated	tau	in	AD,	which	is	of	importance	for	the	development	of	novel	therapeutic	
tools.		
Further	analyses	suggest	that	hyperphosphorylated	tau	or	oligomeric	tau	is	involved	in	
synaptic	loss,	whereas	granular	tau	is	responsible	for	neuronal	loss.	Thus,	different	forms	of	
tau	may	be	involved	in	different	pathological	changes	that	occur	in	tauopathies	(Takashima	
2013).	
	
Tau transgenic mice 
	
In	order	to	study	tau	pathology	in	AD	and	tauopathies	in	general,	tau	transgenic	animals	
have	been	created.	Transgenic	mice	carrying	a	FTDP-17	mutation	in	the	MAPT	gene,	as	seen	
in	familial	forms	of	frontotemporal	dementia	(P301S	mice),	develop	a	progressive	motor	
deficit,	which	is	related	to	the	abundance	of	NFTs	in	the	brainstem	and	spinal	cord	(Allen	et	
al.	2002).	These	filaments	contain	hyperphosphorylated	tau	protein.	While	in	FTDP-17	
patients	nerve	and	glial	cells	are	affected	(Bugiani	et	al.	1999),	in	P301S	mice	the	
accumulation	of	tau	is	restricted	to	nerve	cells	which	is	due	to	the	selective	neuronal	
expression	of	the	tau	transgene	by	the	Thy	1.2	promoter.	This	mouse	model	highlights	the	
role	of	tau	in	neurodegenerative	diseases	and	is	currently	being	used	for	the	development	
of	therapeutic	and	diagnostic	strategies	against	tauopathies.		
It	is	important	to	note	that	the	formation	of	NFTs	is	not	responsible	per	se	for	
neurodegeneration	or	neuronal	death.	In	rat	models	expressing	fragmented	human	tau	(3R	
or	4R),	there	was	accumulated	tau	in	the	brainstem	and	cortex,	and	the	animals	developed	
muscle	weakness	and	wasting	(Zilka	et	al.	2006;	Filipcik	et	al.	2009).	These	studies	highlight	
the	role	of	truncated	tau	in	the	development	of	pathologic	condition	possibly	by	increasing	
the	propensity	for	tau	accumulation.	Better	understanding	of	tau	truncation	and	its	role	in	
tau	toxicity	and	aggregation	is	needed	in	order	to	develop	more	efficient	treatment	
strategies.	
 
 
Prion like properties of amyloid-β and tau 
 
Proteins	are	an	essential	block	of	the	cellular	architecture	and	preserving	their	correct	
structure	enables	proper	cell	functioning	and	survival.	Hence,	it	is	crucial	for	the	cell	to	have	
an	efficient	quality	control	system	of	protein	production,	folding	and	elimination	(Fig.	9).	
Prions	are	infectious	agents	consisting	of	misfolded	prion	proteins,	that	when	misshapen,	
can	trigger	the	aggregation	of	benign	prion	proteins	in	a	chain-reaction,	acting	like	
corruptive	templates	(seeds).	They	can	cause	variety	of	diseases	such	as	Creutzfeldt-Jakob	
disease,	fatal	familial	insomnia,	kuru,	scrapie,	etc.,	and	can	be	of	genetic,	infectious	or	
sporadic	origin	(Jucker	&	Walker	2013b).	However,	they	all	lead	to	neurodegeneration.		
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Figure	9.	Protein	metabolism	in	the	cell	in	a	normal	and	pathologic	(red)	condition.	Adapted	from	(Ciryam	et	
al.	2013).	
	
Amyloid-β	and	tau,	together	with	alpha-synuclein,	TDP-43	and	other	proteins	implicated	in	
neurodegenerative	disorders,	collectively	termed	amyloids	due	to	their	property	to	misfold,	
have	been	lately	recognized	as	having	prion-like	behavior.	This	is	due	to	the	fact	that	they	
are	β-sheet	rich	proteins	that	are	thermodynamically	stable,	have	the	potential	to	aggregate	
and	this	has	been	linked	to	toxicity,	and	they	also	exhibit	strain	specificities.	Most	
importantly,	they	can	seed	naive	amyloidogenic	protein	molecules	with	β-sheet	rich	
aggregates	of	a	similar	protein,	similar	to	prions	(Jucker	&	Walker	2013b).	However,	they	
substantially	differ	from	prions	due	to	the	lack	of	an	infectious	agent	and	the	presence	of	
genetic	factors	implicated	in	AD	(Lahiri	2012).		
Amyloid	formation	in	vitro	starts	with	a	slow	nucleation	phase	that	leads	to	the	formation	of	
the	initial	nucleus	of	an	amyloid	fibril	(Harper	&	Lansbury	1997).	After	this	slow	nucleation	
phase	amyloid	formation	occurs	rapidly	by	recruiting	more	soluble	molecules	and	inducing	
their	abnormal	conformation	(Fig.	10).	With	increasing	size,	the	amyloid	fibril	has	a	
tendency	to	break	and	form	new	prion-like	seeds.	These	in	vitro	observations	of	amyloid	
formation	have	recently	been	translated	to	in	vivo	models	for	both	Aβ	and	tau.		
	
	
	
Figure	10.	Amyloid	formation	starts	with	a	nucleation	phase	(seed	formation)	by	the	addition	of	monomers	
and	oligomers	that	are	conformationally	converted,	until	a	more	stable	growth	phase	is	reached,	leading	
finally	to	fibrils	formation.	The	growing	fibril	can	break	and	then	cause	the	nucleation	of	additional	molecules,	
in	a	self-propagating	manner	(seeding).	Adapted	from	(Jucker	&	Walker	2013b).	
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Amyloid-β seeding 
	
Evidence	for	Aβ	seeding	derives	from	human	and	animal	studies.	Intracerebral	or	peripheral	
injection	of	brain	extracts	from	AD	patients	or	from	aged	APP	transgenic	mice	induced	
amyloidosis	prematurely	in	APP	transgenic	mice	(Kane	et	al.	2000;	Meyer-Luehmann	et	al.	
2006;	Eisele	et	al.	2010).	Injection	of	Aβ	brain	extracts	in	one	brain	region	caused	
amyloidosis	in	synaptically	connected	regions	(Hamaguchi,	2012),	indicating	that	Aβ	
deposition	can	spread	throughout	the	brain.	It	has	been	suggested,	that	the	induction	of	
amyloid-β	aggregation	depends	on	both	the	seed	concentration	and	the	host	expressing	
human	Aβ	(Meyer-luehmann	et	al.	2006).	
In	AD	patients,	Aβ	pathology	starts	in	the	frontal	cortex	and	slowly	progresses	towards	the	
midbrain	and	brain	stem	(Fig.	11)	(Braak	&	Braak	1991).	Lately,	it	was	reported	that	
injections	of	human	pituitary-derived	growth	hormone	caused	amyloid	depositions	in	4	out	
of	8	patients	that	died	from	iatrogenic	Creutzfeld-Jakob	disease	(Jaunmuktane	et	al.	2015).	
However,	it	is	unclear	whether	the	injected	material	contained	also	Aβ	seeds.	In	addition,	
seeding	with	sporadic	or	heritable	AD	derived	brain	homogenates	resulted	in	a	differential	
pathology,	indicating	the	presence	of	distinct	Aβ	strains	(Watts	et	al.	2014).	
Taken	together,	these	studies	suggest	that	aggregation	of	Aβ	can	be	seeded	in	susceptible	
hosts	in	a	way	similar	to	the	molecular	templating	of	prions.		
	
	
	
Figure	11.	Propagation	of	Aβ	plaques	(a,	e)	or	tau	NFTs	(b,	f)	as	a	function	of	age	and	disease	progression,	as	
based	on	autopsy	studies	of	AD	patient	brains.	Adapted	from	(Jucker	&	Walker	2013b).	
	
	
Tau seeding 
	
Similar	to	Aβ,	tau	aggregation	can	be	experimentally	induced	and	transmitted.	Tau	
propagates	from	one	brain	region	to	another	in	a	specific	pattern	in	AD	patients,	and	this	
correlates	with	their	cognitive	decline	(Nelson	et	al.	2012).	NFTs	pathology	starts	from	the	
perirhinal/entorhinal	cortex	(EC),	followed	by	the	hippocampus	and	finally	the	neocortex,	
following	existing	anatomical	connections	between	regions	(Fig.	10)	(Braak	&	Braak	1997).	
In	addition,	propagation	of	tau	pathology	can	be	induced	experimentally	in	animal	models.	
Injection	of	brain	extracts	from	human	P301S	tau	transgenic	mice	into	wild	type	tau	
transgenic	mice,	that	normally	do	not	develop	NFTs,	induced	the	aggregation	of	the	wild	
type	tau	and	tangles	formation	(Clavaguera	et	al.	2009).	Also,	injection	of	recombinant	tau	
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fibrils	or	brain	extracts	containing	aggregated	tau	caused	formation	of	NFTs	that	propagated	
from	the	injection	site	to	connected	brain	regions	in	a	stereotypic	and	time	dependent	
manner	(Iba	et	al.	2013;	Ahmed	et	al.	2014).	This	suggests	that	the	pathological	tau	protein	
conformation	can	be	transmitted	and	locally	propagated	in	a	way	similar	to	prions	(Frost	&	
Diamond	2009).	Tau	seeds	can	be	of	different	sizes,	from	full	length	to	small	soluble	
fragments	(Iba	et	al.	2013;	Lasagna-Reeves	et	al.	2012).	In	addition,	injections	of	brain	
extracts	from	various	tauopathies	in	mice	can	induce	tau	pathology	similar	to	the	one	of	the	
corresponding	human	disease,	indicating	the	presence	of	various	tau	strains	(Clavaguera	et	
al.	2013).	
 
Aβ	and	tau	seeding	is	a	hot	topic	of	research	and	our	understanding	of	their	molecular	
behavior	is	slowly	expanding.	How	could	this	be	used	in	a	clinical	setting,	e.g.	for	improving	
existing	diagnostic	methods?	
	
	
 
Limitations of present AD biomarkers and research questions 
	
Present	biomarkers	are	based	on	decrease	of	neuronal	integrity	and	loss	of	cognitive	
function,	reflecting	late	stage	of	the	disease.	According	to	the	hypothetical	model	of	
dynamic	biomarkers	in	AD,	amyloid	and/or	tau	deposition	precedes	clinical	symptoms	by	
decades	and	occurs	before	biomarker	detectable	pathology	and/or	neurodegeneration	
occurs	(Fig.	12)	(Rosen	et	al.	2010).	What	is	needed	are	biomarkers	to	reflect	very	early	
changes	in	neuronal	integrity,	that	could	also	be	used	to	efficiently	measure	efficacy	of	
drugs	tested	against	AD.	Novel	biomarkers	of	dementias	should	focus	on	detection	of	very	
early	stages	of	the	disease,	which	will	allow	treatment	at	an	earlier	time	point	and	assist	in	
the	selection	of	patients	at	risk	for	progression	(Wang	et	al.	2012).	
Reliable	early	AD	markers,	that	predict	the	disease	occurrence,	and	not	only	its	progression,	
are	still	missing	(Blennow	et	al.	2010b;	Blennow	et	al.	2014).	In	this	sense,	better	
understanding	of	Aβ	and	tau	in	the	CSF	and	improving	its	diagnostic	application	is	of	a	
growing	importance.		
	
	
Figure	12.	Hypothetical	model	for	biomarkers	in	AD.	Currently	detection	is	possible	at	the	beginning	of	
cognitive	impairment	in	patients,	as	earliest	markers	are	a	drop	in	CSF	Aβ		levels	and	abnormal	PET	scan.	
However,	by	this	time	pathological	changes	in	the	brain	have	already	started.	Adapted	from	(Blennow	et	al.	
2014).	
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Amyloid-β in CSF  
	
Reduced	levels	of	Aβ42,	as	well	as	increased	retention	of	amyloid-β	binding	agents	
(Pittsburgh	compound	B)	in	the	brain	during	PET	scan,	are	used	in	current	clinical	practice	to	
identify	AD	patients	(Brys	et	al.	2009;	Blennow	et	al.	2012).	In	addition,	level	of	Aβ42	in	CSF	
obtained	postmortem	inversely	correlate	with	cortical	plaque	load	(Tapiola	et	al.	2009).	
Taken	together,	this	suggests	that	decreased	CSF	concentration	of	Aβ	reflects	an	already	
present	amyloid	deposition	in	the	brain.	Also,	it	has	been	sown	that	in	APP23	transgenic	
mice	levels	of	Aβ40	and	Aβ42	in	the	CSF	decrease	significantly	with	age,	in	parallel	to	the	
appearance	of	senile	plaques	(Maia	et	al.	2013).	
Could CSF Aβ act like a seed? 
	
Aβ	aggregation	can	be	induced	due	to	the	prion-like	properties	of	Aβ.	In	fact,	the	most	
potent	Aβ	seeds	identified	so	far	in	brain	extracts	from	APP23	mice	are	small	and	soluble	Aβ		
assemblies	(Langer	et	al.	2011).	These	findings	suggest	that	soluble	Aβ	in	the	human	brain	
are	also	potent	seeds,	and	that	such	seeds	may	be	found	in	bodily	fluids	such	as	CSF.		In	this	
case,	they	could	serve	as	an	early	diagnostic	biomarker	for	cerebral	amyloidogenesis.		
In	order	to	test	this	hypothesis,	our	collaborators	injected	CSF	from	AD	patients	into	APP23	
transgenic	mice.	However,	they	did	not	observe	any	induction	or	acceleration	of	
amyloidosis,	indicating	that	human	CSF	Aβ		is	not	seed-competent,	in	contrast	to	brain	Aβ			
(Fritschi	et	al.	2014).	In	order	to	test	this	further,	we	injected	susceptible	mice	with	APP23	
mice	derived	CSF,	containing	Aβ	at	higher	amounts	than	the	human	CSF,	and	sacrificed	the	
mice	after	longer	seeding	time.	As	a	result,	we	did	not	see	a	seeding	effect,	confirming	that	
CSF	Aβ	does	not	show	prion-like	properties	in	vivo	(Skachokova	et	al.	2015).		
	
Tau in CSF 
	
In	contrast	to	Aβ,	tau	levels	in	the	CSF	increase	during	AD	progression	(Blennow	et	al.	2014).	
It	has	been	shown,	that	CSF	phospho-tau	correlates	with	the	amount	of	cortical	NFTs	
pathology	in	live	patients	(Tapiola	et	al.	2009).	CSF	total	tau	is	thought	to	be	a	more	dynamic	
marker,	reflecting	the	intensity	of	neuronal	damage,	and	higher	CSF	total	tau	has	been	
associated	with	faster	progression	from	MCI	to	AD	in	demented	patients	(Samgard	et	al.	
2010).	Higher	CSF	tau	has	been	linked	to	AD	and	Creutzfeld-Jakob	disease,	presumably	as	a	
result	of	neuronal	death.	CSF	phospho-tau	possibly	reflects	the	formation	of	tangles	in	the	
brain	and	the	phosphorylation	state	of	tau.		
In	symptomatic	FTD	patients	carrying	a	MAPT	mutation,	CSF	tau	levels	are	slightly	elevated	
but	are	significantly	lower	than	in	AD	patients,	indicating	that	tau	release	is	modified	by	
changes	in	the	tau	protein	that	are	associated	with	tauopathies	(Karch	et	al.	2012).	
Evidences	mostly	based	on	in	vitro	studies	suggest	that	tau	can	be	actively	secreted	from	
the	cells,	even	in	the	absence	of	disease	or	toxicity,	and	in	addition	it	has	been	detected	in	
the	CSF	and	interstitial	fluid	(ISF)	in	humans	and	mice	models	(Yamada	et	al.	2011;	Kang	et	
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al.	2013).	The	exact	mechanism	of	tau	secretion	is	not	clear	yet,	but	tau	has	been	detected	
in	exosomes	of	healthy	and	AD	patients	(Saman	et	al.	2012;	Pooler	et	al.	2013),	implicating	
exosomal	release	as	a	possibility.	
	
Because	of	the	low	amount	of	tau	in	CSF	there	are	rather	contradictory	results	derived	from	
western	blot,	ELISA,	chromatography	and	mass	spectrometry	studies,	regarding	tau	
structure.	One	study	identified	N-terminal	and	mid	domain	tau	fragments	in	the	CSF,	
however	no	fragments	containing	the	C-terminal	or	the	4R	MTBR	region	were	present	(Jr	et	
al.	2013).	At	the	same	time,	a	recent	mass	spectrometry	analysis	revealed	significantly	more	
abundant	mid-domain	tau,	compared	to	the	C-	and	N-terminals	(Barthélemy	et	al.	2016).	
Truncated	tau	may	be	present	in	the	CSF	of	AD	patient,	however	this	is	still	a	topic	of	
research,	and	better	understanding	of	tau	fragmentation,	seeding	and	aggregation	is	
needed.	
	
Could CSF tau act like a seed? 
	
There	are	numerous	experiments	demonstrating	that	brain-derived	tau	can	induce	and	
accelerate	the	aggregation	of	the	host	tau.	Soluble	tau	is	physiologically	present	in	the	CSF,	
which	is	clinically	more	accessible	than	brain	biopsies,	however	it	is	not	known	whether	tau	
there	is	in	an	aggregated,	seed	like	state,	which	could	be	of	a	diagnostic	significance.	To	test	
this,	we	collected	CSF	from	tangle-bearing	P301S	mice	and	injected	it	into	young	pretangle	
stage	P301S	mice.	As	a	result,	we	observed	significantly	higher	number	of	aggregated	and	
hyperphosphorylated	tau	in	the	injected	hippocampus,	indicating	that	CSF	tau	has	seed	like	
properties	(see	Skachokova	et	al.	2016,	in	preparation).	In	a	follow	up	study,	we	tested	
whether	human	AD	CSF	could	induce	tau	aggregation	using	the	same	method,	however	our	
results	are	still	inconclusive	(see	additional	data).	
	
Could fragmented tau increase the toxicity of full length tau? 
	
The	relevance	of	tau	fragmentation	for	neurodegeneration	and	AD	pathogenesis	is	not	
clear,	and	especially	the	relationship	between	truncated	and	full-length	tau.	To	study	this,	
we	generated	an	inducible	mouse	line	expressing	truncated	3R	tau,	and	crossed	it	with	full-
length	tau	carrying	mice	(3R	mice,	or	4R	mice	with	and	without	a	mutation).	As	a	result,	
double	transgenic	mice	exhibited	severe	neuronal	loss	and	motor	palsy,	however	recovered	
once	the	expression	of	fragmented	tau	was	ceased,	except	for	3R	expressing	mice	(Ozcelik	
et	al.	2016).	This	shows	the	importance	of	fragmented	tau	for	toxicity	and	points	at	new	
therapeutic	targets.		
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Aim 
 
Alzheimer’s	disease	(AD)	is	a	deleterious	neurodegenerative	disorder	with	an	increasing	
prevalence.	Currently,	there	are	neither	reliable	early	diagnostic	markers	nor	available	cure.	
	
AD	is	characterized	by	the	aggregation	of	Aβ	and	tau	proteins.	Based	on	previously	
demonstrated	prion-like	characteristics	of	brain	derived	Aβ	and	tau,	here	we	tested	1)	
whether	CSF	Aβ	from	plaque	bearing	mice	could	exhibit	seed-like	properties	in	vivo,	2)	
whether	P301S	mice	CSF	tau	or	3)	human	AD	CSF	tau	could	harbor	seeding	potential	when	
injected	into	susceptible	mice,	and	4)	the	importance	of	tau	fragmentation	in	disease	
toxicity.	
	
These	research	results	could	serve	for	the	development	of	early	diagnostic	bioassays	and	
novel	treatment	options	against	AD.	
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Results 
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Amyloid-β  in the cerebrospinal f luid of APP transgenic mice does not 
show prion-l ike properties 
	
Current	Alzheimer	Research,	2015,	12,	886-891		
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SUPPLEMENTARY	INFORMATION	
	
Supplementary	materials		
 
1.1. ELISA 
Abeta 40 and sAPP levels were measured using Human 6E10 and APPalpha/sAPPbeta Kits 
respectively, both from Meso Scale Discovery, according to the manufacturer’s instructions.	
	
1.2. Mice	
Genotype	 Seed	
Seed	
donor	
age,	mo	
Seeding	
time,	
mo	
App23	 tg	CSF	 18	 14	
App23	 tg	CSF	 24	 14	
App23	 tg	CSF	 24	 14	
App23	 tg	CSF	 24	 14	
App23	 tg	CSF	 18	 21	
App23	 tg	CSF	 18	 21	
App23	 tg	CSF	 24	 21	
App23	 tg	CSF	 24	 21	
App23	 tg	CSF	 24	 21	
App23	 wt	CSF	 3	 21	
App23	 wt	CSF	 24	 21	
App23	 wt	CSF	 24	 21	
App23	 FB	 24	 20	
App23	 FB	 24	 20	
C57BL6	 tg	CSF	 24	 21	
C57BL6	 tg	CSF	 18	 21	
C57BL6	 tg	CSF	 18	 21	
App23	 conc.	tg	CSF	 24	 11	
App23	 conc.	wt	CSF	 24	 11	
App23	 conc.	tg	CSF	 24	 20	
	
Table	S1.	Table	of	all	mice	used	for	quantitative	analysis	in	the	study.	Abbreviations	used:	
tg=transgenic,	wt=wild	type,	FB=forebrain	homogenate,	conc.=concentrated.	
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Supplementary	results	
	
1.3. ELISA	
Sample	 Aβ40,	pg/μl	CSF	 sAPPα,	pg/μl	CSF	 sAPPβ,	pg/μl	CSF	
APP23	CSF	 4.2	 92	 121	
Concentrated	APP23	CSF	 92.6	 2594	 3659	
	
Table	S2.	ELISA	table	of	results.	
	
1.4. Quantification	of	Aβ	pathology	comparing	injected	vs	non-injected	
hippocampus	
Genotype	 Treatment	group	
Seeding	
time,	mo	 N	
Lower	
ratio	 GMR	
Upper	
ratio	 P	value	
APP23	 tg	CSF	 14	 4	 0.77	 0.94	 1.15	 0.56	
APP23	 tg	CSF	 21	 5	 0.79	 0.91	 1.05	 0.19	
APP23	 wt	CSF	 21	 3	 0.65	 0.81	 1.01	 0.06	
APP23	 FB	 20	 2	 0.41	 0.54	 0.70	 0.00***	
C57BL6	 tg	CSF	 21	 3	 0.00	 0.00	 0.00	 NA	
APP23	 conc.	tg	CSF	 11	 1	 0.59	 0.88	 1.30	 0.52	
APP23	 conc.	wt	CSF	 11	 1	 0.72	 1.10	 1.67	 0.66	
APP23	 conc.	tg	CSF	 20	 1	 0.61	 0.92	 1.40	 0.70	
	
Table	S3.	Geometric	mean	ratios	(GMR)	of	amyloid-β	ratios	comparing	non-injected	vs	
injected	hippocampus.	N	indicates	the	number	of	mice	used;	tg=transgenic,	wt=wild	type,	
FB=forebrain	homogenate,	conc.=concentrated;	***	indicates	p<0.001.	
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Abstract 
 
 
Tau is a microtubule stabilizing protein that forms aggregates in many neurodegenerative 
diseases named tauopathies, including Alzheimer’s disease (AD). It was shown that tau 
derived from tauopathy patient brains could induce local protein aggregation in a prion-like 
manner when injected into susceptible mice models. At the same time, increase of tau levels 
in the cerebrospinal fluid (CSF) of AD patients correlates with severity of the disease. 
However, a reliable presymptomatic marker in AD is currently unavailable. A potential prion 
like property of tau in the CSF could have a possible diagnostic application. 
Here we investigated the seed-like potential of tau present in the CSF of mice carrying a tau 
mutation (P301S). We collected CSF from aged, tangle bearing P301S mice and injected it 
into young, pretangle staged P301S mice. As a result, we observed significantly higher 
number of pathologically hyperphosphorylated, AT8 positive NFTs in mice treated with CSF 
from P301S mice. Increased tau pathology was noted anterior and posterior to the 
inoculation site, as well as in the contralateral hippocampus. This suggests that CSF tau can 
exhibit seed like properties in vivo, and can induce tau hyperphosphorylation and fibrillization 
that is transmitted along existing anatomical networks. This knowledge could be useful in the 
development of future diagnostic tools. 
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Introduction 
 
Tau is a natively unfolded protein that promotes microtubules stability in neuronal cells. 
However, in pathological conditions, it becomes hyperphosphorylated, it oligomerizes, 
fibrillates and eventually forms intracellular aggregates. This is characteristic of Alzheimer’s 
disease (AD), but also other neurodegenerative disorders known as tauopathies, including 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal 
dementia (FTD) (Goedert et al. 2010; Mandelkow & Mandelkow 2011; Jucker & Walker 
2013a). In AD patients tau propagates from one brain region to another in a specific pattern 
during the course of the disease (Braak & Braak 1997). Moreover, the injection of brain 
extracts from human P301S tau transgenic mice into wild type human tau transgenic mice 
induces aggregation of the wild type human tau (Clavaguera et al. 2009), suggesting that tau 
aggregation can be transmitted in a prion-like manner. In a number of subsequent studies, 
injection of recombinant tau fibrils or patients’ derived brain extracts containing aggregated 
tau caused formation of neuro fibrillary tangles (NFTs) that propagated from the injection site 
to connected brain regions in a stereotypic and time dependent manner (Liu et al. 2012; de 
Calignon et al. 2012; Clavaguera et al. 2013; Iba et al. 2013; Ahmed et al. 2014). This suggests 
that a pathological conformation or aggregation state of tau can be locally induced by an 
inoculated seed, followed by transneuronal spreading in a way similar to prions (Frost & 
Diamond 2009; Jucker & Walker 2011; Clavaguera et al. 2014). In this light, it has been shown 
that tau aggregates can transfer between cells and might be present in the extracellular 
space (Frost & Diamond 2009; Yanamandra et al. 2013; Pooler et al. 2014).  
Tau is physiologically present in the cerebrospinal fluid (CSF). However, it has remained 
unexplored whether tau in the CSF is soluble, forms oligomers, and/or fibrillizes. CSF 
concentrations of tau and phosphorylated tau are being used for clinical diagnosis of AD, in 
conjunction with CSF amyloid-β levels, cognitive tests, and various forms of brain imaging. 
Increased tau levels in CSF correlate best with cognitive decline in AD patients (Blennow et al. 
1995; Wallin et al. 2006; Blennow et al. 2015). However, most of those markers are 
associated with disease onset, and reliable early, presymptomatic markers, that might 
predict the conversion of mild cognitive impairment to AD, are still missing (Blennow et al. 
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2010b; Blennow et al. 2014). Detection of pathologically conformed tau species in CSF might 
thus be serving as an early diagnostic marker in AD and other tauopathies.  
In order to study the presence of seeding competent tau species in CSF, we here inoculated 
CSF derived from tau transgenic mice into susceptible host mice. CSF was collected from 
P301S mice that carry a tau mutation typical of a familial form of FTD (Allen et al. 2002), and 
injected intrahippocampally into young mice of the same strain. P301S develop NFTs 
progressively with age while their level of CSF tau increases (Yamada et al. 2011). Unilateral 
injection of CSF collected from aged, tangle bearing P301S mice into pre-tangle staged P301S 
mice increased the number of NFTs in both the injected and non-injected hippocampus, as 
compared to littermates inoculated with non-transgenic murine CSF. This data suggests that 
seeding competent tau species with prion-like potential reach the CSF compartment in P301S 
mice. Given the easy accessibility of CSF in human patients, the detection of prionoid tau 
species in the CSF compartment could have a potential future diagnostic application. 
 
 
  
35	
	
Materials and Methods 
 
Mice 
We used homozygous tau transgenic mice expressing the shortest human four-repeat tau 
isoform containing the P301S mutation under the thy1.2 promoter (P301S mice) (Allen et al. 
2002), and aged matched, non-transgenic C57BL/6 control mice. Animal experiments were 
performed in compliance with protocols approved by the official local Committee for Animal 
Care and Animal Use of the Canton of Basel. 
 
Murine CSF collection 
CSF was collected by puncturing the cisterna magna after deeply anesthetizing the animals, 
as previously described (Skachokova et al. 2015). Next, it was spun down at 2500 rpm for 2 
min and the supernatant was collected and immediately frozen. Visibly blood contaminated 
CSF was discarded.  
CSF processing 
Freshly collected human CSF was spun down at 3000 rpm for 2 min to separate cell debris. 
The supernatant was collected and frozen at −80° C. Next it was pooled and concentrated by 
lyophilization (−80° C, 0.01 mbar vacuum pressure, for 24 hours) and reconstituted in sterile 
H2O. The final concentration was measured by ELISA (see Fig. S6). 
 
Stereotaxic surgery 
Three months-old P301S mice and non-transgenic C57BL/6 control mice were anaesthetized 
with a mixture of ketamine (10 mg/kg) and xylazine (20 mg/kg) and placed on a heating pad 
to maintain body temperature during surgery. Mice were injected in the right (R) 
hippocampus (A/P, −2.5 mm from bregma; L, − 2.0 mm; D/V, −1.8 mm) using a Hamilton 
syringe, as previously reported (Clavaguera et al. 2009). Each received a unilateral stereotaxic 
injection of 5 μl concentrated CSF, at a speed of 1.25 μl/min. Following the injection, the 
needle was kept in place for additional 3 minutes before withdrawal. The surgical area was 
cleaned with sterile saline and the incision sutured. Mice were monitored until recovery from 
anaesthesia and checked regularly following surgery. For number of mice used and injected 
material see Table S1. 
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Immunohistochemical analysis 
Following 4 months seeding time, mice were deeply anaesthetized with pentobarbital (100 
mg/kg) and killed by transcardial perfusion with 20 ml cold PBS, followed by 20 ml 4% 
paraformaldehyde in PBS. The brains were dissected and post-fixed overnight. Following 
paraffin embedding, 5 μm coronal sections were prepared. Sections were silver-impregnated 
following the method of Gallyas-Braak to visualize filamentous tau pathology (Gallyas 1971; 
Braak et al. 1988). Haematoxylin and eosin staining was performed for morphological 
analysis. For immunohistochemistry, the following anti-tau antibodies were used: AT8 and 
AT100 (both 1:1000, Thermo Scientific), with secondary antibodies from Vector Laboratories, 
Burlingame, CA (Vectastain ABC kit), as previously described (Ozcelik et al. 2013; Ozcelik et al. 
2016). 
 
Quantification and statistical analysis 
For quantification, on average 7-9 sections per mouse (sections with bad quality were 
discarded) were analyzed at levels comprising the injection site (from -2 to -3 um from 
Bregma), and sections form the injected and non-injected hippocampal side were selected at 
corresponding levels. The number of silver stained tangles and AT8 and AT100 positive 
aggregates was counted using the Cell counter plugin in ImageJ. Then average score per 
group was made. For the AT8 heat map average tau pathology per Bregma level per group 
was calculated and manually color graded. The amounts of granular tau pathology in 3 
hippocampal regions (CA1, CA3, dentate gyrus) at varying Bregma levels were qualitatively 
assessed by two independent researchers and an average score was obtained. Brain images 
that were used and modified are from the Mouse Brain Atlas (Franklin and Paxinos, Elsevier 
2007). All group scores were compared using unpaired Student t-test. P values are reported 
when significant.  
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Results  
 
Parallel to age increase, P301S mice develop hyperphosphorylated tau, later assembled into 
PHFs and NFTs, that is AT8, AT100 and Gallyas positive (Allen et al. 2002) (Fig. S2). In seeded 
mice, we quantified any change in their endogenous pathology based on those markers (Fig. 
1). Injections of CSF from tangle bearing P301S into young, pretangle P301S mice resulted 
into increased number of hyperphosphorylated tau, as compared to wild type CSF seeded 
mice (Fig.2 A, B). Moreover, this effect was present throughout the hippocampus and also 
bilaterally, in the non-injected hippocampal side (Fig.2 E). Also, when we looked at sections 
anterior/around the injection side, we found significant differences between the P301S CSF 
and BL6 CSF injected hippocampi, and also between same groups non-injected sides (Fig.2 A, 
B; p<0.05). This indicates that hyperphosphorylated tau pathology can be transmitted and 
induced via CSF derived from mutated tau expressing mice. 
 
 
F igure 1.  P301S mice normally develop hyperphosphorylated tau positive for AT8 and AT100 antibodies, and 
Gallyas silver stained NFTs in both hippocampi. The magnified immunohistochemical images show cells of the 
CA3 region in the right hippocampus.  
 
Injection of P301S brainstem homogenate (BS) resulted in a higher number of AT8 positive 
neurons in both hippocampal sides, as compared to BL6 BS injections, that was significant in 
the left hippocampus and showed a trend in the right (Fig.2 F). When we focused on sections 
anterior/close to the injection site, we found significant increase in the number of 
hyperphosphorylated tau in both injected and non-injected P301S BS seeding hippocampi, as 
compared to BL6 BS seeded (Fig. 2 C, D, p<0.05 for R and p<0.001 for L). Finally, injection 
with P301S CSF resulted in an effect similar to the P310S brain stem homogenate, even 
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though total tau/ phospho-tau concentrations in the first one are more than a thousand 
times lower (Table S2, Fig. S5).  
 
 
 
Figure	2.	Assessment	of	AT8	positive	tau	in	mice	seeded	mice	with	BL6	CSF	(A,	n=5),	P301S	CSF	(B,	n=5),	P301S	
BS	(C,	n=6)	and	BL6	BS	(D,	n=5).	Hippocampal	pathology	between	groups	and	between	injected	(R)	and	non-
injected	(L)	sides	was	assessed	for	sections	anterior/in	proximity	to	the	 injection	site	(A-D),	or	 for	the	whole	
hippocampus	in	CSF	(E)	and	brain	stem	(F)	seeded	mice.	Color	scale	indicates	the	number	of	NFTs.	*	=	p<0.05,	
#=p=0.07,	as	based	on	unpaired	t-test.	Error	bars	represent	SEMs.	
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Next, we analyzed the AT8 pathology in the CSF seeded mice on different anatomical levels 
and hippocampal subregions. We found a significant effect anterior and in proximity to the 
injection site, specifically in the CA1 and DG regions between the injected hippocampus of 
P301S and BL6 CSF seeded mice (Fig. 3 A, B). Furthermore, in P301S CSF seeded mice we 
found a tendency for higher amount of hyperphosphorilated tau in the injected hippocampus 
CA3 region, versus the contralateral one. When analyzing AT8 load posterior to the injection 
site, we saw significant increase of AT8 positive hyperphosphorylated tau in both the CA1 and 
DG of the injected and non-injected hippocampus in P301S seeded mice (Fig. 3 A, C). This 
shows that injection of mutated tau containing CSF induced a local seeding effect after 4 
months time that was spread throughout the hippocampus based on existing anatomical 
connections. 
 
F igure 3.  Quantification of hyperphosphorylated tau pathology in murine CSF seeded mice in different 
subhippocampal regions. Number of AT8 positive neurons in the CA1, CA3 (incl. CA2) and DG in P301S CSF (n=5) 
and BL6 CSF (n=5) seeded mice is presented as a heat map anterior (comprising sections at -2 to -2.5 from 
Bregma) and posterior (-2.6 to -3 from Bregma) to the injection site (A). Scale bar depicts AT8 load. Number of 
AT8 positive tau is presented as an average value from all sections anterior (B) and posterior to the injection site 
(C). *=p<0.05, #=p=0.07. Error bars represent SEMs. 
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Quantification of AT100 pathology, a later marker of tau hyperphosphorylation (Augustinack 
et al. 2002), also resulted in a significant increase as a result of P301S CSF seeding, as 
compared to BL6 CSF treatment, as seen in the injected hippocampus (Fig.3 A). At the same 
time, there was no significant difference in the amount of Gallyas positive tangles in the right 
hippocampus between P301S and BL6 CSF seeded mice (Fig.3 B), or for BS seeded mice (Fig.3 
C). Thus, our injections induced an increase of endogenous tau hyperphosphorylation and 
formation of prefibrillar tau, but not of late stage Gallyas positive NFTs, in P301S host mice. 
This may be due to the limited seeding time, restricted by the life span of homozygous P301S 
mice due to their progressive motor symptoms (Allen et al. 2002).  
 
 
F igure 4.  Quantification of tau pathology in the injected right hippocampus between conc. P301S CSF (n=5) 
and conc. BL6 CSF (n=5) seeded mice as based on AT100 antibody (A), or Gallyas silver staining (B). The number 
of Gallyas positive NFTs in brain stem seeded mice (P301S BS n=6, BL6 BS n=5) was also analyzed (C). * indicates 
p<0.05, as based on unpaired t-test. Error bars represent SEMs. 
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Discussion 
 
We recently showed that CSF derived amyloid-beta lacks prion-like potential (Skachokova et 
al. 2015; Fritschi et al. 2014). In the present study, we investigated the prion-like potential of 
tau protein present in the CSF of tau transgenic mice and compared it to that in wild type-
mice CSF.  
Induction of tau propagation along synaptically connected regions using brain homogenates 
has been previously reported in P301S mice (Ahmed et al. 2014; Boluda et al. 2014). In order 
to see whether also CSF harbors seeding competent tau species, we here collected CSF from 
aged, tangle bearing P301S mice and injected it into young, pre-tangle staged P301S mice. 
Tau pathology was assessed and compared to littermate mice inoculated with non-transgenic 
mouse CSF. As a result, we observed significantly higher hyperphosphorylated, AT8 positive 
tau, a marker of prefibrilar tau pathology, throughout the hippocampus in mice treated with 
CSF from aged P301S mice. In addition, the observed pathology was present bilaterally in the 
contralateral hippocampus, and also in anterior and posterior directions, and not only 
localized to the injection site. This suggests that mouse CSF tau can exhibit seed like 
properties in vivo, and tau hyperphosphorylation could be induced and transmitted based on 
synaptic connections. These are the first evidences that CSF tau could exhibit prion-like 
characteristics.  
As a result of CSF seeding we observed increased AT8 and AT100 positive structures as 
indicators of pathological, hyperphosphorylated tau (Allen et al. 2002), but no increase in the 
number of late, Gallyas positive NFTs. Tau hyperphosphorylation is an early marker of AD, 
characteristic of the preclinical phase, and precedes tau aggregation by decades in human 
sporadic AD cases (Braak & Del Tredici 2015). It may be the case that because of the limited 
seeding time, an increase in Gallyas positive NFTs was not apparent in our P30S mice, or 
simply CSF tau causes the hyperphoshorylation, but not aggregation of endogenous tau. In 
addition, seeding of AD brain in P301S mice for 3 months increased AT8 signal in the CA3 
region of the injected hippocampus, versus the non-injected one, and tau propagation 
happened in a timely and connectivity based manner (Boluda et al. 2014). These findings are 
similar to our P301S CSF seeding results, however, we also note an increase in other 
hippocamapal subregions as the CA1 and DG that may be due to the variation in the injection 
site and/or extended seeding time. In another study, injection of tau seeds into P301S hetero 
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mice for 6 months induced AT8 hyperphosphorylation in interconnected to the injection site 
regions, resulting in network dysfunction and memory impairment. Importantly, this was 
correlated with the presence of tau oligomers and tau hyperphosphorylation, rather than 
with fully mature NFTs (Stancu et al. 2015), implicating early pathological forms of tau as 
culprits of neuronal dysfunction. Furthermore, hyperphosphorylated tau in the CSF is best 
correlated with cognitive decline, as opposed to total tau (Braak et al. 2013). All this suggests 
that increase in AT8 positive tau per se, as seen in our model and previous studies, can be an 
indicator of both toxicity and seeding effect. 
Currently, it is not known how seeding competent tau reaches the CSF. Previously, it has 
been shown that tau propagates via synaptically connected regions, however the exact 
mechanisms are still unknown (Pooler et al. 2014; Clavaguera et al. 2015). Using an in vitro 
cell model it was demonstrated that phosphorylated tau is actively secreted via exosomal 
release, and also found in vesicles in AD patients CSF (Saman et al. 2012), as well as in 
exosomes isolated from P301S mouse brains (Asai et al. 2015). Furthermore, infusion of tau 
antibodies into tau transgenic mice lateral ventricles reduced tau seeding activity by reducing 
tau hyperphosphorylation and aggregation, implicating extacellular tau in AD pathology as 
seed responsible (Yanamandra et al. 2013). Based on these evidences and our results, it is 
possible that seeding prone tau is released by the neurons and reaches the CSF. In addition, 
we injected our mice with a mixture of P301S CSF and AT8 and AT100 antibodies to see 
whether this would inhibit the observed seeding effect (data pending).  
In conclusion, our results suggest the presence of prion-like tau in the CSF of P301S mice. 
This provides the basis for future studies using human patients CSF, and possibly opens a 
perspective for novel diagnostic approaches. 
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Supplementary Materials  and Results  
	
	
	
	
Injected	mice	
	
Genotype	 Seed	 Seeding	time,	mo	 N	
P301S	 P301S	CSF	 4	 5	
P301S	 BL6	CSF	 4	 5	
P301S	 P301S	BS	 4	 6	
P301S	 BL6	BS	 4	 5	
P301S	 -	 -	 4	
	
Table	S1.	Mice	used	in	the	study	were	injected	with	murine	CSF,	or	murine	brain	stem	(BS)	homogenate	at	3	
months	of	age,	and	sacrificed	4	months	after	(seeding	time).	Some	non-injected	control	mice	were	used	as	
well.	
	
	
	
	
P301S	mice	tau	pathology	
	
	
	
Figure	S2.	Endogenous	tau	pathology	as	analyzed	by	AT8	immunohistochemistry	and	Gallyas	silver	staining	in	4	
and	7	months	old	P301S	mice.	
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Seeding	with	P301S	CSF	and	brain	stem	homogenates	
	
	
	
	
	
Figure	S3.	Qualitative	assessment	of	AT8	positive	tau	pathology	at	different	Bregma	levels.		P301S	mice	seeded	
with	 Bl6	 CSF	 (A),	 P301S	 CSF	 (B),	 P301S	 BS	 (C),	 or	 BL6	 BS	 (D),	were	 evaluated	 at	 -2,	 -2.5	 and	 -2.9	mm	 from	
Bregma,	 corresponding	 to	 the	 left,	 central	 and	 right	 columns.	 Scores	were	made	 as	 based	 on	 average	 AT8	
values	 per	 anatomical	 level	 per	 group.	 Scale	 bar	 depicts	 number	 of	 AT8	 positive	 neurons	 in	 the	 injected	
hippocampus.	Student`s	T-test	between	A	and	B	and	C	and	D	did	not	show	any	significant	differences	for	any	
anatomical	level,	but	at	-2	from	Bregma	the	T-test	between	Bl6	CSF	and	P301S	CSF	seeded	mice	resulted	in	a	
p=0.07.	
	
	
	
	
	
	
	
	
	
	
47	
	
	
Non-seeded	P301S	mice	endogenous	tau	pathology	
	
Figure	S4.	Number	of	silver	positive	tangles	(Gallyas)	and	hyperphosphorylated	tau	(AT8)	containing	neurons	in	
the	right	hippocampus	of	7	months	old,	non-treated	P301S	mice	(n=4).	
	
	
	
Mouse	brain	stem	/	CSF	Tau	concentrations	
	
Seed	 Tau,	ng/ml	 P-Tau,	ng/ml	
P301S	BS	homogenate	 180	553	 308	575	
P301S	CSF	 29	 27	
Conc.	P301S	CSF	 80	 100	
	
Table	S2.	Tau	and	phospho-tau	(P-Tau,	T231)	concentration	of	P301S	brain	stem	homogenates	(n=1),	CSF	
(n=3),a	nd	concentrated	CSF	(n=1),	as	measured	by	ELISA.	
	
	
	
Western	blot		
	
	
Figure	S5.	Western	blot	with	HT7	(against	total	tau)	and	AT8	(hyperphosphorylated	tau)	antibodies	of	non-
diluted	10%	brain	stem	homogenate	(BS),	1000	times	diluted	10%	BS	(dBS),	and	non-concentrated	CSF	from	6	
months	aged	P301S	mice	(n=3).	
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Introduction 
 
Co-expression of truncated and full-length tau induces severe neurotoxicity 
	
Molecular	Psychiatry,	2016,	1-9	
	
	
	
The	author	of	the	present	thesis	performed	some	of	the	behavioral	tests	(grid	test,	object	
recognition	test),	immunofluorescence	(Thioflavine-S,	MG160,	COX)	and	
immunohistochemistry	(VAMP2,	Synaptophysin)	experiments,	all	this	including	data	
collection	and	analysis,	and	contributed	to	the	manuscript	writing.	 	
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Supplemental Information 
 
 
Table S1 
 
 
 
 
(a-c) Overview on the transgenic and co-transgenic mouse lines used for the present studies. Tau 
isoforms expressed are shown. Dark grey boxes indicate the tau repeat domains (3R or 4R isoforms), 
and light grey boxes N-terminal inserts (e.g. ALZ17 ≙ 2N4R).  
The tau cDNA constructs are either driven by a standard Thy1.2 minigene (Thy1.2) or by a modified 
Thy1.2 minigene that contains a tetracycline controlled transcriptional silencer element (Thy1.2-tTS) 
in case of the TAU62 mouse. (a) shows the tau isoforms expressed in single-transgenic lines. (b) 
shows the tau forms of 3 mouse lines co-expressing full-length tau with Δtau. (c) depicts 2 mouse 
lines co-expressing different full-length tau isoforms.  
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Figure S1  
 
 
 
TAU62 mice develop a slowly progressive motor phenotype. 
Motor fitness was assessed on a vertical mesh grid. Time spent on the grid progressively declined in 
TAU62 mice, while B6 controls were unimpaired at 12 months and showed a mild decline at 18 
months of age. 
 
 
 
60	
	
Figure S2  
 
 
 
 
(a) Extensive hyperphosphorylation of tau was seen in the brainstem of old homozygous P301S mice 
by staining with antibodies targeting late phospho-epitopes. Multiple tau tangles and granular 
aggregates were detectable in these mice by Gallyas silver stain. The scale bar in a corresponds to 
50 µm. (b) Western blotting under non-reducing conditions revealed high-molecular tau species in 
paralyzed P301SxTAU62on mice (lanes 6&7); similar tau species were seen in aged tangle bearing 
homozygous P301S mice (lane 5). When tau expression was halted, no more high-molecular tau 
forms were detectable in P301SxTAU62on-off mice (lane 3; Western blot performed with anti-tau 
antibody HT7). (c) Staining with the RD3 antibody targeting Asp421 shows the presence of Δtau in 
the high molecular weight tau species. (d) Sarkosyl-extraction detects only soluble tau species in 
paralyzed P301SxTAU62on mice (“sol”: sarkosyl-soluble tau; “insol”: sarkosyl-insoluble fraction). 
(e-g) Δtau was widely expressed in the spinal cord of P301SxTAU62on mice (e) and phosphorylated at 
the AT8 epitope (f). Upon cessation of Δtau expression, Δtau- and AT8-positive tau was no longer 
detectable (g). The scale bar in e corresponds to 100 µm in e-g. 
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Figure S3 
 
 
(a-m) P301SxTAU62 mice exhibit signs of Golgi disruption, protein missorting and mitochondrial 
clustering. These signs are reversible upon cessation of Δtau expression. Immunohistochemistry 
using antibodies against MG160 (a-f), synaptophysin (g-i), VAMP2 (k-m), and cytochrome C oxidase 
(COX) (n-p), in the hippocampus of non-transgenic mice (B6), 3-week-old paralyzed mice 
(P301SxTAU62on) and recovered mice 6 weeks after cessation of Δtau expression (P301SxTAU62on-
off). The scale bar in a corresponds to 19 µm in d-f, 63 µm in a-c and g-i, and 400 µm in k-m. The 
scale bar in n corresponds to 30 µm for n-p. Arrows in (e) indicate fragmented Golgi structures.  
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Figure S4 
 
 
 
(a-c) Young TAU62 mice exhibit normal sciatic nerves (Masson’s trichrom stain (a); para-
Phenylenediamine (b); immunohistochemistry using 2f11 antibody  (c)). The scale bar in c 
corresponds to 30 µm in a-c.  
(d-g) M. gastrocnemius stained for ATPase (pH 4.2). Dark type 1 fibres (1) and light type 2 fibres (2). 
The scale bar in g corresponds to 50 µm (for d-g). P301S: heterozygous mice transgenic for human 
mutant P301S tau, aged 3 weeks; TAU62: heterozygous mice expressing 3R tau151-421, aged 3 weeks; 
P301SxTAU62on: paralyzed mice, aged 3 weeks; P301SxTAU62on-off: recovered mice, 6 weeks after 
cessation of the expression of Δtau.  
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Figure S5 
 
 
 
(a-i) Co-expression of 3R wild-type tau and Δtau (ALZ31xTAU62 mice) causes paralysis and 
neuropathy, which are not reversed upon cessation of Δtau expression. (a) Paralyzed (aged 3 weeks) 
and non-recovered (3 weeks after cessation of Δtau expression) ALZ31xTAU62 mice (see also video 
S6). (b) Absence of recovery of motor function as assessed by a grid-test of ALZ31xTAU62 mice 
following the removal of doxycycline between 14 and 16 days (blue line; triangles indicate the times of 
euthanasia, n=6). Motor function of heterozygous ALZ31 mice (green line, n=7). (c) Western blot with 
HT7 of brainstem tissue from non-transgenic mice (B6), TAU62 mice, ALZ31 mice and ALZ31xTAU62 
mice. Actin staining was used as the loading control. (d-i) Histological analysis of paralyzed 
ALZ31xTAU62 mice aged 3 weeks, using AT8 (d), AT100 (e), NF200 (f), Holmes-Luxol (HL) (g), 
Masson’s trichrome (h), and Hematoxylin-eosin (HE) stainings (i). The arrow in (g) points to a 
spheroid. The scale bar in d corresponds to 200 µm in d and e; 100 µm in f; 33 µm in g; 50 µm in h, i.  
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Figure S6 
 
 
 
(a,b) Robust expression of the two full-length tau isoforms in P301SxALZ31 (a) and ALZ17xALZ31 (b) 
co-transgenic mice. For comparison, expression of mice co-transgenic for Δtau with full-length tau, as 
well as the respective single transgenic mice is shown. Western blots run under reducing conditions 
using HT7 antibody.  
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Supplemental Experimental Procedures 
 
Antibodies used for immunohistochemistry (IHC) and Western blotting (WB) 
(species is mouse, unless indicated otherwise):  
 
 
Antibody Target Dilution Source 
HT7 human tau 
aa 159-163 
WB 1:4000 
IHC 1:800 
Pierce, Rockford, IL  
#MN1000 
BR134 human tau WB 1:1000 (1) 
Tau-C3 Tau cleaved at 
residue Asp421  
WB 1:1000 
IHC 1:1000 
Santa Cruz Biotechnology, Inc, Dallas, TX  
#sc-32240 
AT8 Tau 
pSer202/Thr205 
WB 1:1000 
IHC 1:800 
Pierce, Rockford, IL #MN1020 
AT100 Tau 
pThr212/Ser214 
WB 1:1000 
IHC 1:500 
Pierce, Rockford, IL #MN1060 
PHF-1 Tau 
pSer396/404 
WB 1:2000 
IHC 1:1000 
Peter Davies, Albert Einstein College of 
Medecine, Bronx, NY 
MC1 Tau 
aa 5-15, 312-322  
IHC 1:100 Peter Davies, Albert Einstein College of 
Medecine, Bronx, NY 
2F11 neurofilament (NF) 
NF-L, NF-H (70kD) 
IHC 1:800 Dako, Glostrup, DK  
#M0762 
NF200 neurofilament (200kD) IHC 1:100 (2) 
GFAP glial fibrillary acidic 
protein 
IHC 1:500 Thermo Fisher Scientific Inc., Kalamazoo, 
MI      
#MS-1407-R7 
Synaptophysin synaptophysin IHC 1:1000 Millipore Corporation, Billerica, MA 
#MAB5258 
MG160 (rabbit) Golgi apparatus IHC 1:1000 Nicholas Gonatas, Pathology and 
Laboratory Medicine, University of 
Pennsylvania, PA 
VAMP2/Synaptobrevin 
2 (rabbit) 
transport vesicles IHC 1:1000 Synaptic system, Goettingen, Germany  
# 104 202 
GAPDH (6C5) GAPDH WB 1:1000 Santa Cruz Biotechnology, Santa Cruz, 
CA, #32233 
ß-actin actin WB 1:5000 Sigma-Aldrich, Saint Louis, MO #A5316 
Cox subunit 1a mitochondrial 
staining 
IHC 1:200 Abcam plc, Cambridge, UK  
#ab14705 
 
Supplemental References:  
 
1. Goedert M, Spillantini MG, Jakes R, Rutherford D, & Crowther RA (1989) Multiple 
isoforms of human microtubule-associated protein tau: sequences and localization in 
neurofibrillary tangles of Alzheimer's disease. Neuron 3(4):519-526. 
2. Probst A, et al. (2000) Axonopathy and amyotrophy in mice transgenic for human 
four-repeat tau protein. Acta Neuropathol 99(5):469-481. 
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Potential	prion-like	properties	of	human	CSF	
	
 
Summary 
 
 We	collected	CSF	 from	AD	and	age	matched	control	patients,	and	 injected	 it	 into	young,	
pretangle	 stage	 P301S	 mice.	 As	 a	 result,	 we	 observed	 a	 local	 increase	 in	
hyperphosphorylated	tau	pathology	in	both	AD	and	control	CSF	treated	mice,	indicating	that	
human	CSF	tau	could	exhibit	prion-like	characteristics.	However,	more	patient	samples	will	
be	 needed	 in	 order	 to	 discriminate	 between	 AD	 and	 non-AD	 cases,	 so	 that	 this	 method	
could	serve	a	future	diagnostic	use.	
 
Results  
	
We	collected	CSF	 from	AD	and	age	matched	control	patients	and	developed	a	protocol	 in	
order	to	concentrate	 it	around	100	times	and	so	to	be	able	to	 inject	 it	 intracerebrally	 into	
the	mice	 (Fig.	1).	We	did	not	 see	a	 significant	difference	 in	 levels	of	 tau	between	AD	and	
Control	patients	CSF	after	the	concentration	procedure	as	measured	by	ELISA	(Fig.	2).		
	
Figure	2.	Levels	of	Total	tau	in	concentrated	and	non-concentrated	human	Control	(n=4)	and	AD	(n=5)	patients	
CSF,	as	measured	by	ELISA.	*	indicates	p=0.04,	however	no	significant	difference	was	found	between	the	
concentrated	CSF	samples,	as	based	on	unpaired	Student	t-test.	
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Next,	we	evaluated	the	effect	of	human	CSF	injections	into	young,	pretangle	bearing	P301S	
mice.	 Initial,	 preliminatry	 quantification	 of	 tau	 pathology	 in	 the	 whole	 hippocampus	
comprising	 the	 injection	 site	 (-2	 to	 -3	 mm	 from	 Bregma)	 did	 not	 show	 any	 significant	
difference	between	 the	 injected	or	contralateral	hippocampus	 in	mice	 treated	with	AD	or	
control	CSF,	as	based	on	AT8	and	Gallyas	staining	(Fig.	3,	A-D).		
	
	
Figure	3.	Injection	of	human	CSF	from	AD	(A,	n=10	mice)	or	control	(B,	n=8	mice)	patients	did	not	result	in	an	
increase	of	AT8	pathology	in	the	whole	hippocampus,	or	between	injected	(R,	left	panels)	and	non-injected	(L,	
right	panels)	hippocampal	side	as	shown	by	immunohistochemistry	(A,	B)	and	quantification	(C).	There	was	no	
difference	in	the	number	of	Gallyas	positive	neurons	between	the	injected	sides	(D).	Error	bars	indicate	SEMs.	
	
However,	there	is	a	high	variation	in	the	endogenously	present	P301S	mice	pathology,	and	
also	a	seeding	effect	can	be	very	 focal	and	hence	not	detectable	 in	 sections	spanning	 the	
whole	hippocampus.	For	this	reason,	next	we	looked	at	AT8	pathology	at	different	Bregma	
levels	and	in	between	different	subhippocampal	regions	of	the	injected	versus	non	injected	
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sites.	As	a	result,	anterior/in	proximity	to	the	injection	site	we	observed	significant	increase	
of	 AT8	 pathology	 in	 the	 right	 CA3	 region	 of	 AD	 CSF	 treated	 mice,	 compared	 to	 their	
contralateral	 CA3	 region	 (Fig.	 4	 A,	 B).	 This	effect	was	 also	 present	 in	 control	 CSF	 seeded	
mice,	even	though	with	smaller	effect	size.		
	
	
Figure	4.	Quantification	of	AT8	 tau	pathology	 in	 the	CA1,	CA3	and	DG	hippocampal	 subregions	at	 -2	 to	 -2.2	
from	Bregma	(A)	revealed	significantly	more	signal	in	the	CA3	of	the	injected	versus	non-injected	side,	in	both	
AD	(n=10)	and	control	(n=8)	CSF	seeded	mice.	The	results	are	depicted	using	a	heat	map	showing	differences	
between	 the	 injected	 and	 non-injected	 hippocampus	 (B)	 in	 AD	 (top	 image)	 and	 Control	 patients	 (bottom	
image),	 as	 color	 grade	 depicts	 p-values.	 Star	 indicates	 the	 injection	 site,	 *	 indicates	 p<0.05,	 **	 indicates	
p<0.001,	as	based	on	Student`s	t-test.	Error	bars	indicate	SEMs.	
	
However,	 even	 if	 total	 hippocampal	 AT8	 load	 was	 above	 the	 baseline	 observed	 in	 non-
treated	 injected	mice	 for	 both	 AD	 and	 Control	 patients	 (see	 Fig.	 S3	 in	 Skachokova	 et	 al.,	
2016),	we	did	not	find	any	significant	difference	between	those	3	groups.	Also,	we	observed	
different	 pathology	 in	mice	 injected	with	 CSF	 from	 the	 same	patient	 that	may	 be	 due	 to	
differences	in	injection	site,	and	variation	in	mice	endogenous	tau	pathology.	
Additional	analysis	showed	no	correlation	between	tau	levels	in	the	CSF	and	AT8	or	Gallyas	
pathology	in	the	injected	hippocampus,	for	both	AD	and	control	CSF	seeded	mice.	
	
These	results	suggest	that	human	CSF	can	harbor	some	seeding	potential	based	on	local	AT8	
increase.	However,	our	assay	is	not	sensitive	enough	to	discriminate	between	AD	and	non-
AD	patients,	and/or	our	control	patients	are	not	optimally	selected,	as	we	lack	CSF	derived	
from	 fully	 asymptomatic	 patients	 (e.g.	 patients’	 spouses).	 This	 could	be	 addressed	by	 the	
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use	 of	 a	 larger	 patient	 cohort	 and	 better	 control	 patients	 selection,	 that	 is	 currently	
ongoing.	
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Discussion 
	
CSF Amyloid-β	lack of seeding  
	
We	reported	that	APP23	mice	injected	with	CSF	derived	from	plaque-bearing	APP23	mice	
for	a	period	of	up	to	21	months	did	not	show	any	increase	in	Aβ	load	at	or	close	to	the	
injection	site,	in	contrast	to	brain	homogenate	seeded	mice.	This	suggests	a	lower	to	absent	
seeding	effect	of	amyloid-β	in	the	CSF,	as	compared	to	the	one	in	the	brain.	In	a	
collaborative	study	the	authors	did	not	find	any	β-amyloidosis	inducing	activity	as	a	result	of	
injection	of	human	AD	CSF	into	APP23	mice,	even	though	they	observed	some	seeding	
activity	in	an	in	vitro	assay	(Fritschi	et	al.	2014).	This	demonstrates	that	seeding	prone	
amyloid-β	does	not	reach	the	CSF	or	is	not	detectable	in	an	in	vivo	seeding	model.		
The	lack	of	detectable	in	vivo	Aβ-inducing	activity	in	human	CSF	can	be	seen	as	a	negative	
result	in	terms	of	developing	an	early	Alzheimer’s	disease	biomarker	assay.	However,	it	is	
reassuring	that	human	CSF,	being	routinely	handled	in	many	laboratories,	does	not	seem	to	
contain	the	self-propagating	Aβ	seeds	that	have	been	shown	to	be	transmissible	under	
laboratory	conditions	(Jucker	and	Walker,	2013),	and	this	knowledge	could	be	used	in	
laboratory	safety	regulations.		
 
Potential prion-like behavior of CSF tau  
	
By	seeding	P301S	CSF	into	young	P301S	mice	we	demonstrated	that	mouse	CSF	tau	exhibits	
seed	like	properties	in	vivo,	as	tau	hyperphosphorylation	was	induced	and	transmitted	along	
existing	anatomical	networks	(Skachokova	et	al.,	2016,	in	preparation).	Using	this	
knowledge	and	methodology,	we	looked	at	the	seed	like	properties	of	human	CSF,	which	
would	be	of	a	diagnostic	importance.	Injection	of	human	CSF	into	young	P301S	mice	did	not	
result	in	the	same	total	hippocampal	increase	of	tau	pathology.	However,	we	noted	a	local	
seeding	effect	when	comparing	the	injected	and	non-injected	sides,	indicating	that	human	
CSF	tau	could	also	harbor	some	seeding	potential.	This,	to	our	knowledge,	is	the	first	study	
so	far	to	demonstrate	that	human	CSF	could	induce	tau	pathology,	even	though	
CSF	obtained	from	AD	patients	was	previously	shown	to	enhance	the	fibril	formation	of	
another	amyloidogenic	protein,	alpha-synuclein	(Ono	et	al.	2007).	Using	this	method,	we	
were	not	able	to	differentiate	between	AD	and	control	patients,	possibly	due	to	the	small	
number	of	patients,	the	strong	endogenously	present	tau	pathology	in	the	mice,	and	the	
limited	sensitivity	of	our	quantification.	Furthermore,	the	selection	of	valid	control	patients	
is	complicated	by	the	fact	that	neuropathological	changes	(including	tangles	formation)	may	
precede	clinical	symptoms,	and	so	may	remain	undiagnosed	(Jack	et	al.	2010).	In	order	to	
check	for	potential	diagnostic	use	of	the	human	CSF	seeding	will	be	needed	more	patient	
samples	and	younger	and/or	healthier	controls.		
The	pathology	we	observed	as	a	result	of	tau	propagation	was	different	when	induced	by	
murine	or	human	CSF,	as	based	on	a	comparison	of	the	injected	and	the	non-injected	
hippocampus.		This	may	be	due	to	the	lower	concentrations	of	tau	in	human	CSF,	or	there	
may	be	structural	varieties	in	the	tau	strains	they	contain.	P301S	mice	carry	a	mutation	that	
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is	typical	of	frontotemporal	dementia,	which	is	characterized	by	pathology	different	from	
AD.	It	has	been	suggested	that	brain	samples	from	different	tauopathy	patients	may	seed	
tau	aggregation	in	different	structures/	cell	types,	and	possibly	propagate	in	distinctive	
ways,	due	to	the	presence	of	different	tau	strains	(Boluda	et	al.	2014).	It	may	be	the	case	
that	AD	and	P301S	derived	CSF	contains	different	tau	variants,	and	hence	the	different	
spreading	patterns	(local	versus	the	whole	hippocampus).		
	
CSF	tau	molecular	structure	has	been	studied	with	contradicting	results,	most	probably	due	
to	the	low	tau	concentration	in	CSF.	Some	studies	report	predominance	of	a	mid-domain	
tau	fragment,	rather	than	C	and	N-terminal	fragments	or	a	full	length	tau	(Barthélemy	et	al.	
2016),	but	also	N-terminal	fragments	have	been	identified,	with	no	tau	containing	a	
microtubule	binding	site	present	(Meredith	et	al.	2013).	It	was	shown	that	tau	molecules	
containing	the	repeat	domain	are	able	to	form	fibrils	at	a	different	rate	form	P301L	mutant	
tau	mice	in	vitro	(Shammas	et	al.	2015).	It	could	be	that	human	CSF	and	P301S	CSF	contain	
tau	forms	with	different	molecular	structures,	hence	different	propagation	patterns.	Further	
structural	studies	will	be	needed	to	shed	more	light	into	this,	as	well	as	between	AD	and	
control	patients	CSF.	Our	results	suggest	that	CSF	in	both	P301S	mice	and	aged	humans	
contains	seeding	competent	tau	species,	however	their	exact	structure	is	yet	to	be	revealed.	
	
How	does	pathological	tau	enter	the	CSF	compartment?	It	has	been	shown	that	tau	
propagates	via	synaptically	connected	regions,	via	cell	to	cell	transmission,	however	the	
exact	mechanisms	are	still	unknown	(Pooler	et	al.	2014;	Clavaguera	et	al.	2015).	Using	an	in	
vitro	cell	model	it	was	demonstrated	that	phosphorylated	tau	is	actively	secreted	via	
exosomal	release,	and	also	found	in	vesicles	in	AD	patients	CSF	(Saman	et	al.	2012),	as	well	
as	in	exosomes	isolated	from	P301S	mouse	brains	(Asai	et	al.	2015).	Furthermore,	infusion	
of	tau	antibodies	into	tau	transgenic	mice	lateral	ventricles	reduced	tau	seeding	activity	by	
reducing	tau	hyperphosphorylation	and	aggregation,	implicating	extracellular	tau	in	AD	
pathology	as	seed	responsible	(Yanamandra	et	al.	2013).	Based	on	these	evidences,	it	is	
possible	that	seed	prone	tau	is	released	by	the	neurons	and	reaches	the	CSF	(Fig.	13),	
however	it	is	not	known	whether	this	parallels	the	intracellular	pathology	and	further	
studies	need	to	be	done	to	test	its	diagnostic	value.	
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Figure	13.	A	hypothetical	model	of	Aβ	and	tau	secretion	into	the	CSF.	The	proteins	are	normally	released	from	
the	neurons	into	ISF	and	then,	through	the	cells	of	the	choroid	plexus,	into	the	CSF.	In	AD,	aggregation	prone,	
oligomeric	Aβ	is	contained	into	plaques	and	does	not	reach	the	CSF.	In	contrast,	pathogenic	tau	(aggregated,	
hyperphosphorylated	(p-tau),	truncated	(?	tau)),	and	soluble	tau,	possibly	reach	the	CSF	compartment,	where	
they	can	be	clinically	accessed.	
	
Another	important	question	concerns	the	nature	of	the	secreted,	pathological	tau.	
Previously,	it	has	been	reported	that	tau	species	harboring	prion-like	potential	consist	of	
large	and	aggregated	hyperphosphorylated	tau	forms	(Clavaguera	et	al.	2009;	Jackson	et	al.	
2016),	but	oligomeric	tau	has	been	implicated	just	as	well	(Lasagna-Reeves	et	al.	2012).	
However,	immunization	with	an	anti-phospho	tau	antibodies	in	tauopathy	mice	models	
reduced	tau	pathology	(Bi	et	al.	2011;	Boimel	et	al.	2010),	indicating	phosphorylated	and/or	
aggregated	tau	as	the	seed	inducing	species.	Phosphorylated	tau	is	present	in	the	CSF	and	
used	currently	in	diagnostics,	however,	so	far	there	are	no	evidences	for	the	presence	of	
aggregated	tau	in	there,	even	though	the	presence	of	aggregated	amyloids	in	CSF	from	
Parkinson`s	disease	patients	has	recently	been	shown	(Horrocks	et	al.	2016).	Further	
seeding	studies	using	AD	patients	CSF	and	brain	samples	are	needed	to	elucidate	the	nature	
of	the	seed	inducing	tau	species,	and	possibly	help	the	development	of	therapeutics	to	
inhibit	tau	propagation.	
	
The	CSF	of	AD	patients	may	contain	fragmented	forms	of	tau,	that	are	not	normally	present	
in	healthy	individuals,	as	demonstrated	by	some	studies	(Jr	et	al.	2013;	Barthélemy	et	al.	
2016).	In	this	sense,	tau	truncation	as	detected	by	its	presence	in	the	CSF	may	serve	as	
indicator	of	early	pathological	changes	associated	with	the	disease.		
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Our	additional	results	point	to	the	importance	of	truncated	tau	in	disease	toxicity	and	
neurodegeneration,	especially	when	it	is	expressed	together	with	full	length	tau	(Ozcelik	et	
al.	2016).	It	has	been	previously	shown	that	truncation	of	tau	increases	its	propensity	to	
aggregate,	and	it	has	been	suggested	that	cleaved	tau	may	seed	the	aggregation	of	full	
length	tau	(Abraha	et	al.	2000;	Spires-Jones	2011).	It	is	possible	that	the	seeding	properties	
of	P301S	CSF	are	due	to	the	presence	of	tau	fragments,	however	more	structural	studies	will	
be	needed	to	elucidate	this.	In	this	light,	we	have	injected	P301S	mice	with	brain	
homogenates	from	mice	expressing	fragmented	tau	and	also	both	fragmented	and	full	
length	tau,	to	see	its	effect	on	the	host	pathology.	This	analysis	is	currently	ongoing.	
	
The	toxicity	of	truncated	tau	in	combination	with	full	length	tau	at	molecular	to	behavior	
levels	in	our	mice	model	is	striking,	however	even	more	surprising	is	the	fact	that	this	effect	
is	reversible.	This	study	implicates	oligomeric	tau	as	a	toxic	mediator	in	tauopathy	and	
points	at	inhibitors	of	tau	oligomerization	and	truncation	as	possible	therapeutic	tools.	
	
In	conclusion,	our	results	implicate	CSF	tau	as	a	candidate	for	the	development	of	future	
diagnostic	bioassays	based	on	its	seeding	properties.	However,	its	clinical	use	in	AD	
diagnosis	and	possibly	presymptomatic	diagnosis	still	remain	to	be	clarified.	
In	addition,	tau	fragmentation	plays	an	important	role	in	tau	mediated	toxicity,	and	
represents	a	promising	target	for	the	development	of	novel	therapeutic	tools.	
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Materials and methods 
	
	
Mice	
	
APP23	mice	are	expressing	the	human	APP	gene	(751-aa	isoform),	containing	the	Swedish	
double	mutation	at	positions	670/671	(KM->NL),	under	the	control	of	the	murine	Thy-1.2	
promoter.	The	APP751	cDNA	was	inserted	into	the	blunt-ended	XhoI	site	of	the	expression	
cassette	containing	the	Thy-1.2	gene	that	was	microinjected	into	pronuclei	(Sturchler-
Pierrat	et	al.	1997).	Heterozygous	APP23	mice	were	interbred	with	C57BL/6J	mice	and	
transgenic	littermates	were	identified	by	genotyping.		
	
P301S	mice	are	expressing	the	shortest	human	four-repeat	tau	isoform	(4R0N)	containing	
the	P301S	mutation	(Allen	et	al.	2002).	The	mouse	line	was	generated	by	using	a	cDNA	
encoding	a	383	amino	acids	isoforms	of	human	tau,	subclonied	into	a	murine	Thy	1.2	
expression	vector	using	a	XhoI	restriction	site.	Transgenic	mice	were	generated	by	
microinjection	into	pronuclei	of	(C57BL/6J	x	CBA/ca)	F1	generation.	The	founders	were	
identified	via	PCR	analysis,	and	these	were	interbred	with	C57BL/6J	mice.	For	seeding	
experiments,	homozygous	P301S	were	used.	For	investigating	the	role	of	fragmented	tau,	
heterozygous	P301S	were	used.	
	
Tau62	mice	expressing	an	inducible	fragmented	tau	were	generated	by	co-injection	of	two	
Thy	1.2	minigenes	based	constructs	into	C57BL/6J	oocytes.	The	Thy	1.2-tTS	construct	was	
produced	by	replacing	exon	2	of	the	mouse	Thy	1.2	promoter	by	a	tetracycline	controlled	
transcription	silencer	element	(tTS).	The	Thy	1.2-TRE-tau	construct	contained	a	tetracycline	
responsive	element	(TRE)	upstream	of	the	human	wild-type	tau	cDNA	encoding	amino	acids	
151	to	421	of	a	3-repeat	domain	spanning	human	wild-type	tau	fragment	(Fig.	14).	A	total	of	
6	positive	Tau62	founders	were	identified	and	the	inducible	expression	of	human	tau	was	
assessed	by	western	blot	and	immunohistochemistry.	Lines	62-2	and	62-48	exhibited	
comparable	and	robust	fragmented	tau	expression	only	in	the	presence	of	doxycycline.		
	
	
Figure	14.	Genetic	construct	used	for	the	generation	of	TAU62	mice.	
	
P301SxTAU62	double	transgenic	mice	have	been	obtained	by	crossing	P301S	mice	with	
Tau62	line.	All	double	transgenic	mice	were	heterozygous	for	the	transgenes	of	interest.	
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Chow	containing	500mg/kg	doxycycline	was	provided	ad	libitum	to	induce	fragmented	tau	
expression.	All	animal	experiments	were	performed	in	compliance	with	protocols	approved	
by	the	official	local	Committee	for	Animal	Care	and	Animal	Use	of	the	Canton	of	Basel.	
	
	
DNA	isolation	and	Genotyping	
	
Small	pieces	of	mice	toes	or	ears	were	incubated	in	lysis	buffer	containing	0.1	mg/ml	
Proteinase	K	(Macherey-Nagel,	Germany)	overnight	in	Eppendorf	Thermomixer	comfort	
shaker	(700	rpm,	55°C).	The	solution	was	centrifuged	(13000	rpm,	5	min)	and	750	μl	of	the	
supernatant	was	mixed	with	750	μl	of	isopropanol	by	inverting	the	tubes.	Next,	the	mix	was	
spun	down	(13000	rpm,	10	min),	the	supernatant	was	discarded	and	the	pellet	was	washed	
with	75%	ethanol	and	centrifuged	again	(13000	rpm,	10	min).	The	remaining	pellet,	
containing	the	DNA,	was	dried	on	Eppendorf	Thermomixer	comfort	shaker	(55°C,	5-10	min)	
and	finally	resuspended	in	250	μl	dH2O	(50°C,	1h).	
Lysis	buffer	composition:	100	mM	Tris	pH	8.0,	5	mM	EDTA,	0.2%	SDS,	200	mM	NaCl,	sterile	
H2O.	
Mice	from	the	APP23	line	were	analyzed	for	the	presence	of	the	transgene	by	PCR.	For	the	
PCR	mixture	were	used:	
2μl	of	10pmol/μl	Forward	primer	(‘5-CCG	ATG	GGT	AGT	GAA	GCA	ATG	GTT-3’)	
2μl	of	10pmol/μl	Reverse	primer	(‘5-GAA	TTC	CGA	CAT	GAC	TCA	GG-3’),	both	primers	from	
(Eurofins	MWG,	Germany)	
12.5μl	of	TopTaq	Master	Mix	(Qiagen,	Germany)	
6.5μl	sterile	H2O	
and	2μl	of	DNA	
	
PCR	program:	
	
Temperature,	°C	 Time,	s	 Cycles	
94	 120	 1	
94	 45	 1	
60	 60	 	
35	
	
72	 45	
94	 45	
72	 300	 1	
4	 ∞	 	
	
The	program	was	run	on	a	PTCM100	machine	(MJ	Research,	Canada)	and	finally	the	PCR	
product	was	run	on	a	1.5%	agarose	gel	using	a	100bp	DNA	ladder	(Roche,	Switzerland)	at	
150	V.	DNA	was	stained	using	SybrSafe	(Thermo	Fisher	Scientific,	USA).	
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Murine	CSF	collection	and	processing	
	
For	CSF	sampling,	mice	were	deeply	anesthetized	with	a	mixture	of	ketamine	(10	mg/kg,	
Ketalar®,	Pfizer,	USA)	and	xylazine	(20	mg/kg,	Rompun®	2%,	Bayer,	Germany),	placed	
ventrally	on	a	tube	holder	rack	and	the	hair	around	the	neck	was	wet.	Next,	a	vertical	
incision	was	made	on	the	skin	on	the	neck,	and	the	visible	splenius	and	rectus	muscles	were	
pulled	aside	until	the	pia	mater	surrounding	the	cisterna	magna	was	visible.	Secondly,	the	
membrane	was	punctured	using	an	injection	needle	(25	G	Agani,	Terumo,	Belgium)	and	CSF	
was	collected	using	a	10	μl	pipette	for	an	interval	of	2	min.	Finally,	the	liquor	was	spun	down	
at	2500	rpm	for	2	min	and	the	supernatant	was	collected	and	immediately	frozen.	Visibly	
blood	contaminated	CSF	was	discarded.		
Next,	CSF	from	different	mice	was	pooled	together	and	concentrated	by	lyophilization	at	
−80°C,	0.01	mbar	vacuum	pressure,	overnight,	using	an	Alpha	2-4	LSCplus	Christ	dryfreezer	
(Millrock,	USA).	The	dried	product	was	reconstituted	in	sterile	H2O	with	a	5-fold	
concentration	ratio.	CSF	tau	concentration	was	measured	by	ELISA.	
	
Stereotaxic	surgery	
	
Three	months-old	P301S,	APP23	or	non-transgenic	C57BL/6	control	mice	were	anesthetised	
with	a	mixture	of	ketamine	(10	mg/kg,	Ketalar®,	Pfizer,	USA)	and	xylazine	(20	mg/kg,	
Rompun®	2%,	Bayer,	Germany),	and	placed	on	a	heating	pad	to	maintain	body	temperature	
throughout	the	surgery	(Harvard	Apparatus,	USA).	Skin	on	the	head	was	cut	open	by	a	
vertical	incision,	and	mice	were	head	fixed	on	a	stereotaxic	frame	(David	Kopf	Instruments,	
USA).	Animals	eyes	were	protected	using	Lacrinorm	gel	during	the	procedure	
(Bausch&Lomb,	USA)	Next,	the	precise	injection	site	was	determined	and	a	hole	was	
carefully	drilled	into	the	skull,	avoiding	any	rupture	of	the	pia	mater.	Mice	were	injected	in	
the	right	(R)	hippocampus	(A/P,	−2.5	mm	from	Bregma;	L,	−	2.0	mm;	D/V,	−1.8	mm)	using	a	
10	μl	glass	syringe	(701N,	Hamilton,	USA),	as	previously	reported	(Clavaguera	et	al.	2009).	
Each	received	a	unilateral	stereotaxic	injection	of	5	μl,	at	a	speed	of	1.25	μl/min.	Following	
the	injection,	the	needle	was	kept	in	place	for	additional	3	minutes	before	being	withdraw.	
The	surgical	area	was	cleaned	with	sterile	saline	and	the	incision	site	closed	using	Prolene	6-
0	C1	sutures	(Ethicon,	USA).	Mice	were	monitored	until	recovery	from	anesthesia	and	
checked	regularly	following	surgery.		
	
	
Perfusion	and	brain	preparation	
	
Following	the	previously	specified	seeding	time,	mice	were	deeply	anaesthetized	by	an	
intraperitoneal	injection	with	a	mixture	of	100	mg/kg	ketamine	(Ketalar®,	Pfizer)	and	10	
mg/kg	xylazine	(Rompun®	2%,	Bayer),	followed	by	100	mg/kg	sodium	pentobarbital	
(Pentothal®
	
0.5g,	Ospedalia	AG).	Next	they	were	transcardially	perfused	with	0.01M	cold	
phosphate-buffered	saline	(PBS,	Bichsel),	followed	by	4%	paraformaldehyde	in	PBS.	After	
perfusion,	brain	was	quickly	removed,	cut	in	coronal	plane	anterior	to	the	hippocampus,	
and	both	brain	parts	were	immersion	fixed	in	4%	paraformaldehyde	overnight,	and	finally	
embedded	in	paraffin.	
	
78	
	
	
	
	
Immunohistochemical	analysis	
	
Following	paraffin	embedding,	the	brain	containing	the	whole	hippocampus	was	cut	into	4	
μm	coronal	sections	(starting	at	-2	Bregma	to	-3	Bregma,	as	defined	by	the	Mouse	Brain	
Atlas	by	G.	Paxinos	and	K.	Franklin)	in	a	serial	manner	using	a	sliding	microtome	(Leica	
SM2000R,	Leica,	Germany).	Sections	were	shorty	placed	on	a	floating	bath	(60°C)	to	
straighten	and	mounted	on	histological	slides	(Leica	IP	S,	Leica,	Germany),	and	finally	let	dry	
overnight	at	37°C.	
After	drying,	 sections	were	deparaffinised	by	placing	 them	 subsequently	 in	Xylol	 (20	min,	
from	Biosystems,	Switzerland),	100%	EtOH	 (3	min),	96%	EtOH	 (2x3	min)	and	 in	70%	EtOH	
(2x3	min),	followed	by	washing	in	PBS.	For	82E1	immunohistochemistry,	pretreatment	with	
100%	Formic	acid	for	5	min	was	applied.	In	order	to	mask	antigenic	sites,	antigen	retrieval	
was	performed	using	Citric	acid	buffer	pH=6.0	(Pro	Taps)	for	30	min	at	90°C.	After	blocking	
in	2.5%	normal	horse	serum	(Vector	Laboratories)	for	30	min	at	room	temperature,	sections	
were	 incubated	 with	 primary	 antibody	 diluted	 in	 PBS	 at	 4°C,	 overnight.	 The	 next	 day,	
sections	were	washed	in	Tris/PBS	solution	(3x5	min)	and	incubated	with	ImmPRES
	
Reagent	
peroxidase	 (Vector	 Laboratories,	 USA)	 for	 1h	 at	 RT.	 Next,	 sections	 were	 washed	 with	
Tris/PBS	 (3x5	min)	and	stained	using	chromogen	 ImmPACT
	
NovaRED
	
Peroxidase	substrate	
kit	(Vector	Laboratories,	USA),	as	reaction	time	was	controlled	under	a	microscope.	Sections	
were	 then	 washed	 with	 H2O	 to	 stop	 the	 reaction	 and,	 in	 some	 cases,	 slides	 were	
counterstained	 with	 hematoxyline	 (J.T.	 Baker).	 Finally,	 sections	 were	 dehydrated	 in	 70%	
ethanol	 (1	min),	96%	EtOH	(2x1	min),	100%	EtOH	(2x1	min)	and	xylol,	and	mounted	using	
Pertex®	 medium	 (Biosystems,	 Switzerland).	 Pictures	 of	 sections	 were	 taken	 using	 an	
Olympus	DP73	(Olympus,	USA)	microscope.		
For	immunohistochemistry	(IHC),	immunofluorescence	(IFL)	and	western	blot	(WB),	the	
following	primary	antibodies	were	used:		
	
Antibody	
	
Species	 Antigen	 Concentration/Use	 Source	
82E1	
	
mouse	 Amyloid-β	 1:1000/	IHC	 Demeditec,	Germany	
AT8	 mouse	 PHF	tau	(Ser202/Thr205)	 1:800/	IHC	
1:1000/	WB	
Thermo	Scientific,	USA	
AT100	
	
mouse	 PHF	tau	(Ser212/Thr214)	 1:1000/	IHC	 Thermo	Scientific,	USA	
HT7	
	
mouse	 Human	tau159-163	 1:1000/	WB	 Pierce,	USA	
TauC3	
	
mouse	 Truncated	tau	(Asp421)	 1:1000/	IHC,	WB	 Santa	Cruz	Biotechnology,	USA	
MC1	 mouse	 tau5-15	and	tau312/322	 1:1000/	IHC	 P.	Davies,	Albert	Einstein	
College	of	Medicine,	NYC,	USA	
PHF1	 mouse	 Phosphoresine396-404	 1:1000/	IHC	
1:2000/	WB	
P.	Davies,	Albert	Einstein	
College	of	Medicine,	NYC,	USA	
RD3	(8E6/C11)	 mouse	 Human	3R	tau209-224	 1:3000/	IHC	
1:4000/	WB	
Millipore,	USA	
RD4	(1E1/A6)	 mouse	 Human/mouse	4R	tau275-
291	
1:100/	IHC	
1:4000/	WB	
Millipore,	USA	
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VAMP2	
	
rabbit	 Postsynaptic	vesicles	 1:1000/	IHC	 Synaptic	System,	Germany	
MG160	 rabbit	 Golgi	apparatus	 1:1000/	ICH,	IFL	 N.	Gonatas,	Univeristy	of	
Pennsylvania,	USA	
Synaptophysin	
	
mouse	 Presynaptic	vesicles	 1:1000/	IHC	 Millipore,	USA	
β-actin	
	
mouse	 Actin	 1:5000/	WB	 Sigma-Aldrich,	USA	
Cox1a	
	
mouse	 Mitochondrial	protein	 1:200/	IFL	 Abcam,	UK	
	
 
Gallyas	silver	staining		
Sections	were	silver-impregnated	following	the	method	of	Gallyas-Braak	to	visualize	
filamentous	tau	pathology	(Gallyas	1971;	Braak	et	al.	1988).	After	deparaffinisation	and	
rehydration	as	previously	described,	sections	were	incubated	in	3%	Periodic	Acid	(Sigma-
Aldrich,	USA)	for	30	min	at	room	temperature.	Second,	slides	were	washed	in	d	H2O	for	2	
min	and	incubated	in	1%	Alkaline	Silver	solution	(1M	sodium	hydroxide,	0.6M	potassium	
iodide,	1%	silver	nitrate	solution,	all	from	Merck,	Germany),	for	10	min	at	room	
temperature.	Third,	slides	were	incubated	in	ABC	solution,	shaking	occasionally,	and	
reaction	time	(tangles	colored	form	brown	to	black)	was	controlled	under	a	microscope.	
	
ABC	solution:	
Solution	 Composition	 Concentration,	%	 Producer	
A	 Sodium	carbonate	
anhydrous	
5	 Merck,	Germany	
	
B	
Ammonium	nitrate	 0.14	 Merck,	Germany	
Silver	nitrate	 0.2	 Merck,	Germany	
Tungstosilicic	acid	 1	 Sigma-Aldrich,	USA	
	
	
C	
Ammonium	nitrate	 0.14	 Merck,	Germany	
Silver	nitrate	 0.2	 Merck,	Germany	
Tungstosilicic	acid	 1	 Sigma-Aldrich,	USA	
37%	formaldehyde	
solution	
0.74	 Merck,	Germany	
	
Fourth,	reaction	was	stopped	by	incubation	in	0.5%	Acetic	Acid	(Merck,	Germany)	for	30	
min	at	room	temperature.	Fifth,	slides	were	washed	in	dH2O	and	incubated	in	5	%	Sodium	
thiosulfate	(Merck,	Germany)	for	5	min	at	room	temperature.	Next	slides	were	washed	in	
cold	tap	water,	followed	by	hematoxylin	eosin	staining,	dehydration	in	EtOH	and	mounting,	
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as	previously	described.	
	
Hematoxylin	and	Eosin	Staining		
After	deparaffinisation	and	rehydratation,	sections	were	rinsed	in	cold	tap	water	and	
stained	in	hematoxylin	for	5	to	8	min.	After	washing	in	cold	tap	water	and	decolorizing	
shortly	in	alcohol-HCl,	the	slides	were	washed	again	in	cold	tap	water	and	placed	for	10	min	
in	warm	water	until	blue.	Next	sections	were	immersed	in	1%	erythrosine	B	solution	(RAL	
diagnosis)	for	2-3	min,	washed	shortly	in	cold	tap	water,	dehydrated	in	EtOH	concentration	
gradient	and	finally	placed	in	xylol	before	mounting.		
	
Immunofluorescence	and	confocal	microscopy	
	
After	deparaffinisation	and	rehydration,	followed	by	antigen	retrieval	and	blocking,	sections	
were	incubated	with	primary	antibody	overnight	at	4°C.	Next	day,	after	washing	with	PBS	
(3x5	min),	secondary	anti-mouse	Alexa	Fluor	488	or	594	antibody	(Invitrogen,	USA)	was	
added	in	concentration	1:1000	in	dark	for	2h,	at	room	temperature.	Finally,	slides	were	
washed	again	in	PBS	(3x5	min),	mounted	with	Dapi	containing	medium	(ProLong®,	
Invitrogen,	USA)	and	kept	in	dark	at	4°C.	
Sections	were	observed	using	a	fluorescent	Olympus	BX43F	(Olympus,	USA)	microscope	and	
images	 were	 acquired	 using	 an	 A1	 confocal	 microscope	 (Nikon,	 USA).	 All	 images	 were	
acquired	at	the	same	exposure	and	were	automatically	aligned	using	the	stitching	tool	in	the	
Axiovision	 LE	 software.	Once	 acquired,	 all	 images	were	 opened	 in	 ImageJ	 (NIH,	USA)	 and	
were	normalized	and	the	threshold	was	set	automatically.	
	
	
Human	CSF	collection	and	patient	characteristics	
	
CSF	was	collected	within	a	clinical	trial	set	up	at	the	Memory	Clinic	of	the	University	Hospital	
Basel.	 The	 trial	was	approved	by	 the	 local	 Ethics	Commission	of	 the	Canton	of	Basel,	 and	
recruitment	 was	 limited	 to	 patients	 with	 a	 Mini	 Mental	 Score	 >19/30	 for	 reasons	 of	
informed	 consent	 (Pachet	 et	 al.	 2010).	 Subsequent	 patients	 examined	 for	 potential	
neurodegenerative	dementia	at	the	Memory	Clinic	were	included	in	the	study.	Up	to	15	ml	
of	 CSF	 per	 patient	 were	 collected	 by	 lumbar	 puncture	 after	 obtaining	 written	 informed	
consent	 of	 the	 patient	 and	 a	 care-giver.	 Final	 clinical	 diagnosis	was	 based	 on	multimodal	
assessments	including	neuropsychological	testing,	brain	MRI	imaging,	CSF	tau	and	Aβ	level	
measurements,	and,	in	selected	cases,	rbf-SPECT	imaging.		
For	 purpose	 of	 inoculation	 into	 mice,	 CSF	 samples	 derived	 from	 the	 patients	 with	 the	
highest	(“AD	CSF”	group,	n=5)	and	the	lowest	(“Control	CSF”	group,	n=4)	probability	of	AD-
related	 cognitive	 decline	 were	 selected.	 AD-CSF	 samples	 were	 obtained	 from	 2	 patients	
fulfilling	the	actual	criteria	for	“Probable	AD	dementia	with	high	biomarker	probability	of	AD	
etiology”	(McKhann	et	al.	2011),	one	patient	with	“Probable	AD	dementia	based	on	clinical	
criteria”	as	well	as	one	patient	with	“MCI	core	clinical	data”	(Albert	et	al.	2011),	both	with	
high	 evidence	 for	 neuronal	 injury.	 The	 4	 patients	 attributed	 to	 the	 “Control-CSF”	 group	
fulfilled	the	criteria	for	“Dementia-unlikely	due	to	AD”	or	“MCI-unlikely	due	to	AD”	without	
biomarker	evidence	for	AD”	(McKhann	et	al.	2011;	Albert	et	al.	2011)	.	Cognitive	decline	of	
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control	 patients	was	 related	 to	 non-neurodegenerative	 causes	 (e.g.	 vascular	 dementia	 or	
alcohol	 abuse).	 For	 the	 ongoing	 human	 CSF	 study,	 we	 are	 collecting	 samples	 from	
cognitively	healthy	spouses	of	demented	patients.	
	
	
Human	CSF	processing	
	
Freshly	collected	human	CSF	was	spun	down	at	3000	rpm	for	30	min	to	separate	cell	debris.	
The	supernatant	was	collected	and	frozen	at	−80°	C.	In	order	to	obtain	reasonable	tau	levels	
in	 the	 small	 volumes	 that	 could	be	 injected	 into	mouse	brains,	 human	CSF	 samples	were	
concentrated.		To	this	end,	10	ml	of	human	CSF	per	patient	was	lyophilized	at	−80°	C,	0.01	
mbar	 vacuum	pressure,	overnight,	using	an	Alpha	2-4	 LSC	plus	 lyophilizer	 (Millrock,	USA).	
The	dried	product	was	reconstituted	 in	1	ml	sterile	H2O	and	dialyzed	 in	order	to	decrease	
salts	 content	 using	 Float-A-Lyzer®	 G2	 (Spectrum	 Labs,	 USA)	 during	 24h	 with	 3	 buffer	
changes,	 again	 lyophilized,	 and	 finally	 reconstituted	 in	 H2O.	 The	 final	 concentration	 was	
measured	by	ELISA.	
	
	
Figure	1.	Human	CSF	was	collected	by	a	lumbar	puncture	(10ml	on	average),	and	8ml	were	used	for	
subsequent	lyophilisation,	dialysis,	and	lyophilisation	again,	and	finally	dissolved	in	66μl	sterile	water,	with	a	
theoretical	concentration	factor	of	120x.	
	
	
ELISA	
	
Tau	 and	 phospho-tau	 levels	 were	 measured	 using	 the	 MSD	 Phospho	 (Thr231)/Total	 Tau	
Multi-Spot	assay	(Meso	Scale	Discovery,	USA)	and	analyzed	using	Sector	Imager	(Meso	Scale	
Discovery,	USA),	according	to	the	manufacturer’s	guidelines.		
Amyloid-beta40	and	APP	levels	were	measured	using	Human	6E10	and	APPalpha/sAPPbeta	
Kits	respectively	(Meso	Scale	Discovery,	USA)	according	to	the	manufacturer’s	instructions. 
 
	
Western	blot	
	
Following	perfusion	with	PBS,	one	half	of	the	mouse	brain	was	dissected	into	forebrain	and	
brain	stem	and	immediately	frozen	in	liquid	nitrogen	or	on	dry	ice.	The	brain	tissue	was	
homogenized	using	Ultraturrax	T8	(IKA	Labortechnik)	in	1:10	weight:volume	of	TBS-
Complete	buffer	containing	20	mM	Tris	pH	7.5	(Biomol),	137	mM	NaCl	(Merck)	and	1	tablet	
complete	mini	protease	inhibitor	cocktail	(Roche,	Switzerland).	This	was	followed	by	
sonication	(90%	power,	10%	cycle	and	10	pulses)	using	Sonopuls	(Bandelin,	Germany).	The	
homogenized	samples	were	spun	down	at	5000	rpm	for	30	min	and	the	supernatant	was	
collected	and	aliquoted.		
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7%	Nupage®	Bis	Tris	gel	(Thermo	Scientific,	USA)	was	loaded	with	5	μl	Precision	Plus	Protein	
All	Blue	standard	(Bio	Rad,	USA)	and	with	the	sample	mix	containing	the	protein,	4	μl	
Nupage	LDS	sample	buffer,	and	sterile	water	up	to	20	μl	final	volume.	The	gel	was	run	at	
125	V	for	90	min.	Next,	samples	were	transferred	on	a	PVDF	membrane	with	the	iblot	gel	
transfer	stack	(Novex®,	Life	Technologies,	USA)	using	the	iblot	(Invitrogen,	USA)	for	7	min.	
Next,	unspecific	binding	epitopes	were	blocked	with	5%	non-fat	milk	in	PBS-T	for	1h	at	room	
temperature,	followed	by	incubation	with	primary	antibody	overnight	at	4°C	on	a	shaker.	
After	washing	with	PBS-T	(3x5	min),	the	membrane	was	incubated	with	horseradish	
peroxidase	(HRP)	conjugated	secondary	antibody	for	1h	at	room	temperature.	Then,	
membranes	were	washed	three	times	with	PBS-T	(3x5	min),	and	detected	by	
electrochemiluminescence	(ECL)	(GE	Healthcare,	USA)	using	Azure	c300	Western	blot	
imager	(Azure	Biosystems,	USA).	Images	were	analyzed	using	ImageJ	(NIH,	USA)	
	
	
Quantification	and	statistical	analysis	
	
For	quantification	we	used	8	to	10	brain	sections,	depending	on	the	tissue	quality.	Sections	
were	selected	for	each	animal	from	the	injected	right	(R)	and	lateral	left	(L)	hemisphere	at	
corresponding	Bregma	levels,	spanning	the	hippocampus	(starting	anterior	to	the	injection	
site	 at	 -1.8	 mm	 and	 extending	 to	 -3.1	 mm	 posterior),	 with	 at	 least	 50	 μm	 distance	 in	
between.		
The	hippocampal	Aβ-plaque	burden	(the	area	occupied	by	all	plaques	as	percent	of	the	total	
area)	was	estimated	for	each	section	using	ImageJ	software.	Pictures	were	transformed	into	
8-bit	 images,	 hippocampus	 was	 selected	 as	 a	 region	 of	 interest,	 threshold	 was	 set	
automatically	 and	 the	 area	 and	mean	grey	 value	were	measured.	 In	order	 to	 analyse	 the	
effect	of	CSF	inoculation	on	Aβ-plaque-burden,	linear	mixed-effects	models	were	used.	We	
thereby	 compared	 the	 injected	 to	 the	 non-injected	 hippocampal	 side.	 Aβ-plaque	 burden	
served	as	dependent	variables,	independent	variables	were	hippocampal	sides	(injected	vs.	
non-injected).	 Subject	was	 treated	as	a	 random	 factor.	 Side	was	nested	within	 time	point	
and	 group.	 To	 achieve	 approximately	 normal	 distribution,	 Aβ-plaque	 burden	 values	were	
log-transformed	(zeros	were	replaced	by	half	the	smallest	value).	Results	were	expressed	as	
geometric	mean	ratios	(GMR)	with	corresponding	95%	confidence	intervals	and	p-values.	A	
p-value	<	0.05	was	considered	as	significant.	All	analyses	were	done	using	R	version	3.0.1	(R	
Foundation	for	Statistical	Computing,	Vienna,	Austria).	
For	 quantification	 of	 tau	 pathology,	 the	 number	 of	 AT8,	 AT100	 and	Gallyas	 positive	NFTs	
was	counted	using	the	Cell	counter	plugin	 in	 ImageJ.	Then	average	score	from	all	sections	
per	 animal	 and	 per	 group	 was	 made.	 For	 the	 AT8	 heatmap	 average	 tau	 pathology	 per	
Bregma	level	per	group	was	calculated	and	manually	colour	graded	using	the	Windows	Paint	
program.	 The	 amounts	 of	 granular	 tau	 pathology	 in	 3	 hippocampal	 regions	 (CA1,	 CA3,	
dentate	 gyrus)	 at	 varying	 Bregma	 levels	 were	 qualitatively	 assessed	 by	 two	 independent	
researchers	and	an	average	score	was	obtained.	Brain	images	that	were	used	and	modified	
are	from	the	Mouse	Brain	Atlas	(Franklin	and	Paxinos,	Elsevier	2007).	All	group	scores	were	
compared	using	unpaired	Student	t-test.	P	values	are	reported	when	significant.		
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Grid	test	
	
Testing	of	the	mice	grid	reflex	and	motor	strength	was	performed	on	the	grid	test.	For	this	
purpose,	animals	were	placed	on	a	vertical	mesh	grid	and	the	latency	to	fall	off	was	
measured	during	a	maximum	time	of	180s.	Mice	were	tested	3	times	with	at	least	5	min	
interval	in	between	trials,	and	an	average	score	per	day	was	made.	
	
Object	recognition	test	
	
To	assess	the	impact	of	fragmented	tau	on	short	term	memory,	mice	were	tested	in	the	
object	recognition	test.	After	handling	the	animals	first	for	a	couple	of	days	to	reduce	their	
stress	level,	they	were	placed	in	a	squared	open	field	box	(48x48x40cm)	under	dim	light	
conditions,	and	let	freely	explore	it.	Because	the	animals	displayed	initially	some	freezing	
behavior,	the	habituation	phase	was	extended	during	3	consecutive	days	for	15	min,	until	
no	signs	of	stress	were	present	and	they	were	freely	moving	into	the	box.	The	behavior	was	
recorded	using	a	video	camera	placed	above	the	box.	During	the	following	two	days,	two	
identical	objects	were	introduced	at	diagonal	corners	of	the	field,	and	mice	were	let	explore	
them	until	a	20s	exploration	criteria	for	each	was	reached	(Leger	et	al.	2013),	for	a	
maximum	training	duration	of	10	min.	Next	day	the	animals’	short	term	memory	was	tested	
by	replacing	one	of	the	familiar	objects	with	a	novel	one,	and	the	time	spent	exploring	each	
object	during	a	period	of	6	min	was	video	recorded.	Video	scoring	was	done	manually	by	a	
researcher	blind	to	the	genotype	using	VLC	media	player	(VideoLAN,	France),	and	as	
exploration	criteria	was	used	nose	sniffing/touching	of	the	object	at	a	distance	of	2	cm	or	
less	(Leger	et	al.	2013).	For	both	training	and	test	phases	were	used	10	cm	high	objects	
composed	of	the	same	material	(Lego	Duplo®,	Billund,	Denmark),	and	the	position	of	the	
novel	and	familiar	objects	were	randomized	across	groups.	
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